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The IDRS sample is a sentinel group of people 
aged 18 years or older who injected illicit drugs 
at least once monthly in the preceding six 
months and resided in the capital cities of 
Australia. Participants were recruited via 
advertisements in needle syringe programs 
and other harm reduction services, as well as 
via peer referral. The results are not 
representative of all people who use illicit 
drugs, nor of use in the general population. 
Data were collected in 2021 from June-July. 
Interviews in 2020 and 2021 were delivered 
face-to-face as well as via telephone, due to 
COVID-19 restrictions being imposed in 
various jurisdictions throughout the data 
collection periods. This methodological 
change should be factored into all 
comparisons of data from the 2020 and 
2021 sample relative to previous years.  
Sample Characteristics 
The IDRS sample in 2021 (N=888) differed in 
some ways to the sample in 2020. Despite 
these differences, the 2021 sample 
predominantly identified as male (65%) with a 
mean age of 45, mostly consistent with the 
national profile in previous years. A significant 
change was observed in the drug of choice 
nominated by participants (p<0.001), with 
methamphetamine (45%) surpassing heroin 
(40%) for the first time since monitoring began. 
There was also a significant change in the drug 
injected most often in the past month 
(p<0.001), with methamphetamine being 
nominated as the drug injected most often by 
53% of the sample, the highest per cent since 
monitoring began. Similarly, there was an 
increase in weekly or more frequent 
methamphetamine use compared to 2020 
(58% versus 48%; p<0.001) whereas a 
decrease in weekly or greater use of heroin 
(37% versus 51%; p<0.001) was reported. 
COVID-19 Impact 
This brief section was included to summarise 
data collected specifically related to COVID-19 
and associated restrictions; subsequent 
sections reflect standard annual reporting. In 
2021, 46% of the national sample had been 
tested for SARS-CoV-2 by the time of interview 
and no one had been diagnosed with the virus. 
The majority (72%) of participants were ‘not at 
all’ worried about contracting COVID-19, and 
18% of participants reported that they had 
quarantined for 14 or more days due to a 
possible exposure in the past 12 months. Ten 
per cent had received at least one dose of the 
COVID-19 vaccine by the time of interview.  
Heroin 
Recent (i.e., past six month) use of any heroin 
decreased from 63% in 2020 to 50% in 2021 
(p<0.001), although there was large 
jurisdictional variation (e.g., n≤5 of participants 
in the NT sample versus 78% in the ACT 
sample). Median frequency of use also 
decreased, from 96 days in 2020 to 72 days in 
2021 (p=0.008). Further, there were significant 
changes in perceived purity (p<0.001) and 
availability (p=0.024), with more participants 
perceiving heroin to be of ‘high’ purity (24%) 
and ‘very easy’ to obtain (40%) in 2021 
compared to 2020 (14% and 35%, 
respectively). The price of a point of heroin also 
increased, from $70 in 2020 to $80 in 2021 
(p=0.026).  
Methamphetamine 
Recent use of any methamphetamine has 
been gradually increasing since 2010. In 2021, 
80% reported recent use, a significant increase 
from 2020 (72%; p<0.001) but similar to the per 
cent reporting use in 2019 (78%). Crystal was 
the most common form of methamphetamine 
used by participants (78%), followed by powder 
(12%) and base (3%). Relative to 2020, 
frequency of use increased from a median of 
48 days to 72 days in 2021 (p=0.008), the 
highest frequency of use observed since 
monitoring began. The price of a point of 
crystal methamphetamine decreased from 
$100 in 2020 to $50 in 2021 (p<0.001), 






returning to the median price observed 
between 2016-2019. There were significant 
changes in perceived purity (p<0.001) and 
availability (p<0.001). Specifically, more 
participants perceived purity to be ‘high’ (14% 
in 2020 versus 28% in 2021) and availability as 
‘very easy’ (17% in 2020 versus 46% in 2021).  
Cocaine 
Recent use of cocaine and frequency of use 
has generally decreased amongst the national 
sample since the beginning of monitoring (35% 
in 2001). In 2021, recent use of cocaine 
remained stable relative to 2020 (15% versus 
17% in 2020). Median frequency of use 
remained stable at three days.  
Cannabis 
In 2020 and 2021, recent use of cannabis was 
reported by the lowest per cent since 
monitoring began (67%, respectively). 
Frequency of use remained stable at a median 
of 180 days (160 days in 2020). Just over half 
(51%) of people who had recently used 
cannabis reported using cannabis daily (48% 
in 2020). The price of a gram was stable for 
both bush and hydroponic cannabis, whereas 
a significant decrease was observed for the 
price on an ounce of bush in 2021 ($200) 
relative to 2020 ($250; p=0.038).  
Pharmaceutical Opioids 
Non-prescribed use of most forms of 
pharmaceutical opioids has mainly remained 
stable or significantly declined since monitoring 
of each opioid first began. In 2021, morphine 
was the most common pharmaceutical opioid 
used in a non-prescribed context (16%). Six 
per cent of the national sample reported recent 
non-prescribed fentanyl use, stable from 6% in 
2020. There was a significant decrease of 
those reporting recent use of any methadone 
in 2021 relative to 2020 (35% versus 43% in 
2020; p=0.002), although non-prescribed use 
remained stable at 13%.  
Other Drugs 
Use of NPS has remained low and stable over 
the period of monitoring. In 2021, 7% reported 
recent use, the lowest per cent since 
monitoring began. Use of ‘new’ drugs that 
mimic the effects of cannabis and opioids were 
reported by 4% and 1%, respectively. Recent 
use of e-cigarettes (18%) significantly 
increased compared to 2020 (13%; p=0.002), 
whilst use of all other monitored drugs 
remained stable. One-in-ten reported recent 
use of GHB /GBL/1,4-BD. 
Drug-Related Harms and Other Associated 
Behaviours 
Nearly one in five participants (17%) reported 
overdosing on any drug in the preceding year, 
most commonly heroin (9%). Over one in three 
(37%) had ever been trained in naloxone 
administration and 4% of the sample had ever 
been resuscitated with naloxone by somebody 
trained through the take-home naloxone 
program. One-quarter of the sample reported 
driving within three hours of consuming an illicit 
or non-prescribed drug in the past six months 
and 4% reported driving while over the 
perceived legal limit of alcohol. In 2021, 6% of 
participants reported receptive sharing of a 
needle or syringe and 10% reported distributive 
sharing in the past month. One in four 
participants (26%) reported to have 
experienced injection-related problems in the 
past month, most commonly nerve damage 
(11%). Nearly two-fifths of the sample were 
currently in any drug treatment (37%), a 
decrease relative to 2020 (48%; p<0.001). 
Over two-fifths of participants in 2021 (44%) 
reported that they had received a hepatitis C 
virus (HCV) antibody test in the past year, 40% 
had received an RNA test and 9% reported 
having a current HCV infection. Fourteen per 
cent of participants reported that they or 
someone else had ever tested the content 
and/or purity of their illicit drugs in Australia, 
with 8% undertaking this in the past year. Self-
reported mental health problems in the past six 
months and past month criminal activity 
remained stable in 2021 (47% and 39%, 
respectively).
2021 SAMPLE CHARACTERISTICS
NALOXONE AND HARM REDUCTION
OTHER HARMS AND HELP-SEEKING 
INJECTING RELATED RISKS AND HARMS
In 2021, 888 people from all 
Australian capital cities participated 
in IDRS interviews.
The mean age in 2021 was 45, 
and 65% identified as male.
IDRS participants’ knowledge of, 
and participation in, the take home 
naloxone program remained stable 
in 2021.
In the 2021 sample, 17% had 
experienced a non-fatal overdose 
in the previous 12 months and 37% 
were currently in drug treatment.
IDRS participants’ use of drugs the 
day before interview participation, 
2021.
In 2021, 8% of the sample reported 
that they or someone else had tested 
the content and/or purity of their illicit 
drugs in Australia in the past year.
Of those who reported having heard of 
naloxone, 29% had used naloxone to 
resuscitate someone who had 
overdosed.
In the 2021 sample, 88% were 
unemployed and 16% had no fixed 
address.
In the sample, 47% self reported 
a mental health problem in the six 
months prior to interview, and 28% 
had seen a mental health 
professional.
In 2021, 6% of the IDRS sample 
reported receptive needle sharing, 
and 10% reported distributive needle 
sharing.
  
The number of people who re-used 
their own needles reduced from 44% 
in 2020 to 38% 2021.
Participants were recruited on the 
basis that they had injected drugs 
at least monthly in the previous 
6 months.
Of those who reported ever 
accessing naloxone, 39% received 
intramuscular naloxone and 47% 
intranasal naloxone.
Of those who commented, the top 
three most common mental health 
issues reported were depression 
(64%), anxiety (49%) and PTSD 
(25%).
In the national sample, 34% of 
participants reported injecting 
someone else after injecting 
themselves. 
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In 2021, 26% of the national sample 
reported having an injection-related 
health issue in the month preceding 
interview.
26%





Past 6 month use of heroin 
decreased to 50% in the 2021 
IDRS sample (63% 2020).
Of those who had recently 
consumed heroin, 75% used it 
weekly or more often, a decrease 
from 80% in 2020.
Past 6 month use of any (80%) and 
crystal (78%) methamphetamine 
increased since 2020, while recent 
use of powder (12%) and base (3%) 
decreased.
Past 6 month use of non-prescribed 
pregabalin was stable at 14% in the 
2020 IDRS sample and 16% in 2021.
Past 6 month use of non-prescribed 
morphine was stable at 15% in the 
2020 IDRS sample and 16% in 2021.
Of those who had recently used any 
form of methamphetamine, 74% used 
it at least weekly, an increase from 
68% in 2020.
The median reported price for a point 
of methamphetamine was $50 in 
2021, a decrease from $100 in 2020.
Past 6 month use of non-prescribed 
fentanyl was stable at 6% in the 2020 
IDRS sample and 6% in 2021.
Past 6 month use of any cannabis 
was stable at 67% in the 2020 IDRS 
sample and 67% in 2021.
Of people who had consumed 
cannabis in the last 6 months, 
97% had smoked it. 
Of those who had consumed 
cannabis recently, half reported daily 
use (51%).
Of those who could comment
84% perceived heroin to be ‘easy’ or 
‘very easy’ to obtain, up from 77% in 
2020.
Of those who could comment, 86% 
perceived crystal methamphetamine 
to be ‘easy’ or ‘very easy’ to obtain in 
2021, an increase from 48% in 2020.
Past 6 month use of GHB/GBL/1,4-BD 
was stable at 10% in the 2020 IDRS 
sample and 10% in 2021.
Of those who could comment
88% perceived hydro and 78% 
perceived bush to be ‘easy’ or ‘very 
easy’ to obtain.
50%
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The median reported price for a 
point of heroin was $80 in 2021, an 
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The Illicit Drug Reporting System (IDRS) interviews are conducted 
annually with a sentinel group of people who regularly inject drugs, 
recruited from all capital cities of Australia (N=888 in 2021). The 
results from the IDRS interviews are not representative of all people 
who consume drugs, nor of illicit drug use in the general population, 
but this is not the aim of these data. Rather, these data are intended 
to provide evidence indicative of emerging issues that warrant further 
monitoring. These findings should be interpreted alongside analyses 
of other data sources for a more complete profile of emerging trends 
in illicit drug use, market features, and harms in Australia.    







The Illicit Drug Reporting System (IDRS) is an ongoing illicit drug monitoring system which has been 
conducted in all states and territories of Australia since 2000, and forms part of Drug Trends. The 
purpose of the IDRS is to provide a coordinated approach to monitoring the use, market features, and 
harms of illicit drugs.  
The IDRS is designed to be sensitive to emerging trends, providing data in a timely manner, rather 
than describing issues in extensive detail. It does this by studying a range of data sources, including 
data from annual interviews with people who regularly inject drugs and from secondary analyses of 
routinely-collected indicator data. This report focuses on the key results from the annual interview 
component of the IDRS.  
Methods 
IDRS 2000-2019 
Full details of the methods for the annual interviews are available for download. To briefly summarise, 
participants were recruited using multiple methods (e.g., needle and syringe programs (NSP) and 
peer referral) and needed to: i) be at least 17 years of age (due to ethical requirements); ii) have 
injected non-prescribed or illicit drugs at least monthly during the six months preceding interview; and 
iii) have been a resident of the capital city in which the interview took place for ten of the past 12 
months. Interviews took place in varied locations negotiated with participants (e.g., treatment services, 
coffee shops or parks), and were conducted using REDCap (Research Electronic Data Capture), a 
software program to collect data on laptops or tablets. Following provision of written informed consent 
and completion of a structured interview, participants were reimbursed $40 cash for their time and 
expenses incurred.  
IDRS 2020-2021: COVID-19 Impacts on Recruitment and Data Collection 
Given the emergence of COVID-19 and the resulting restrictions on travel and people’s movement in 
Australia (which first came into effect in March 2020), face-to-face interviews were not always possible 
due to the risk of infection transmission for both interviewers and participants. For this reason, all 
methods in 2020 were similar to previous years as detailed above, with the exception of: 
1. Means of data collection: Interviews were conducted via telephone across all jurisdictions in 
2020, with some jurisdictions (NT and TAS) also offering face-to-face interviews; 
2. Means of consenting participants: Participants’ consent to participate was collected verbally 
prior to beginning the interview; 
3. Means of reimbursement: Participants were given the option of receiving $40 reimbursement 
via one of three methods, comprising bank transfer, PayID or gift voucher, where completing 
the interview via telephone; and 
4. Age eligibility criterion: Changed from 17 years old to 18 years old. 
 
In 2021, a hybrid approach was used whereby interviews were conducted either face-to-face (with 
participants reimbursed with cash) or via telephone/videoconference (with participants reimbursed via 
bank transfer or other electronic means). Face-to-face interviews were the preferred methodology, 
however the introduction of restrictions by various jurisdictional governments throughout the 
recruitment period meant that telephone interviews were conducted when required (i.e., in accordance 






with government directives) or when requested by services. Consent was collected verbally for all 
participants. 
A total of 888 participants were recruited across capital cities nationally (June-July, 2021). The sample 
sizes recruited from the capital city in each jurisdiction were: Sydney, NSW n=150; Melbourne, VIC 
n=148; Adelaide, SA n=101; Canberra, ACT n=100; Hobart, TAS n=95; Brisbane and Gold Coast, 
QLD n=101; Darwin, NT n=94; and Perth, WA n=99. Of this number, 196 interviews were conducted 
via telephone: Sydney, NSW n=62; Melbourne, VIC n=27; Adelaide, SA n=2; Canberra, ACT n=0; 
Hobart, TAS n=0; Brisbane, QLD n=73; Darwin, NT n=0; and Perth, WA n=32. 
Data Analysis  
For normally distributed continuous variables, means and standard deviations (SD) are reported; for 
skewed data (i.e., skewness > ±1 or kurtosis > ±3), medians and interquartile ranges (IQR) are 
reported. Tests of statistical significance have been conducted between estimates for 2020 and 2021. 
Note that no corrections for multiple comparisons have been made and thus comparisons should be 
treated with caution. Values where cell sizes are ≤5 have been suppressed with corresponding 
notation (zero values are reported). References to ‘recent’ use and behaviours refers to the past six-
month time period.  
 
Interpretation of Findings 
Caveats to interpretation of findings are discussed more completely in the methods for the annual 
interviews but it should be noted that these data are from participants recruited in capital cities, and 
thus do not reflect trends in regional and remote areas. Further, the results are not representative of 
all people who consume illicit drugs, nor of illicit drug use in the general population, but rather are 
intended to provide evidence indicative of emerging issues that warrant further monitoring.  
This report covers a subset of items asked of participants and does not include jurisdictional-level 
results beyond estimates of recent use of various substances, nor does it include implications of 
findings. These findings should be interpreted alongside analyses of other data sources for a more 
complete profile of emerging trends in illicit drug use, market features, and harms in Australia (see 
section on ‘Additional Outputs’ below for details of other outputs providing such profiles). 
Differences in the methodology, and the events of 2020-2021, must be taken into consideration 
when comparing 2020-2021 data to previous years, and treated with caution.  
 
Additional Outputs 
Infographics from this report are available for download. There are a range of outputs from the IDRS 
which triangulate key results from the annual interviews and other data sources and consider the 
implications of these findings, including jurisdictional reports, bulletins, and other resources available 
via the Drug Trends webpage. This includes results from the Ecstasy and Related Drugs Reporting 
System (EDRS), which focuses on the use of ecstasy and other stimulants. 
Please contact the research team at drugtrends@unsw.edu.au with any queries, to request additional 
analyses using these data, or to discuss the possibility of including items in future interviews. 










Participants were asked questions about select sociodemographic 
characteristics, as well as key drug use characteristics of interest.  






Sample Characteristics  
In 2021, there was a significant change in recruitment methods compared to 2020 (p<0.001), with 
fewer participants being recruited via NSPs (54% versus 63% in 2020), and more via word-of-mouth 
(38% versus 25% in 2020). Seventeen per cent of the 2021 sample had taken part in the 2020 
interview (16% of the 2020 sample had taken part in the 2019 interview; p=0.884). 
A significant change in gender identity was observed in 2021 compared to 2020 (p=0.027), with more 
participants identifying as male (65% versus 59% in 2020). The mean age of the sample was 45 years 
(SD=10; 44 years in 2020; SD=9; p=0.216) (Table 1). The majority of the sample (88%) were 
unemployed at the time of interview (88% in 2020; p=0.724), although nearly three-fifths (58%; 62% 
in 2020; p=0.085) of the sample reported having received a post-school qualification(s). The vast 
majority of participants (95%) reported receiving a government pension, allowance or benefit in the 
past month, stable from 2020 (94%; p=0.660). The median weekly income in 2021 was $358 
(IQR=300-460), significantly lower than reported in 2020 ($500; IQR=421-555; p<0.001).  
There was a significant change in drug of choice in 2021 compared to 2020 (p<0.001), with 
methamphetamine (45% versus 33% in 2020) surpassing heroin (40% versus 50% in 2020) for the 
first time since monitoring began in 2000 (Figure 1). There was also a significant change in the drug 
injected most often in the past month (p<0.001), with methamphetamine reported as the drug injected 
most often by over half of the sample (53% versus 41% in 2020), the highest percentage recorded 
since monitoring began (Figure 2). Inversely, there was a decrease in participants reporting that 
heroin was the drug injected most often in the past month (34% versus 46% in 2020). 
In addition, there was an increase in weekly or more frequent consumption of crystal 
methamphetamine in 2021 compared to 2020 (57% versus 47%; p<0.001), the highest percentage 
recorded since monitoring began (Figure 3). In contrast, significantly fewer participants reported 
weekly or more frequent use of powder methamphetamine (6%; 8% in 2020; p=0.022) and heroin 




















Table 1: Demographic characteristics of the sample, nationally and by jurisdiction, 2019-2021 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=902 N=884 N=888 N=150 N=100 N=148 N=95 N=101 N=99 N=94 N=101 
 2019 2020 2021         
Mean age 
(years; SD) 44 (10) 44 (9) 45 (10) 47 (10) 44 (9) 44 (9) 42 (9) 45 (10) 45 (10) 45 (12) 44 (10) 
% Gender   *         
Female 31 40 34 28 30 28 28 43 42 35 47 
Male 68 59 65 70 70 72 71 57 58 65 53 
Non-binary 1 1 0 - 0 0 - 0 0 0 0 
% Aboriginal and/or 
Torres Strait Islander 22 18 23* 25 19 26 16 20 13 37 28 
% Sexual identity            
Heterosexual 87 86 82 73 88 83 83 93 85 77 80 
Homosexual 3 4 4 9 - 6 - - - - - 
Bisexual 8 8 11 13 8 10 13 6 10 19 12 
Queer 1 1 1 - - - - 0 0 - - 
Other 1 1 1 - - 0 0 0 - 0 - 

























qualification(s)^ 57 62 58 63 57 42 59 59 68 52 65 
% Current employment 
status            
Unemployed 88 88 88 89 88 96 86 88 86 83 83 
Full time work 1 3 2 - - - - - - 7 - 
% Past month gov’t 
pension, allowance or 
benefit  
93 94 95 97 98 96 96 96 92 91 93 
Current median 



































accommodation            
Own home (inc.renting)~ 70 69 66 82 75 44 65 73 53 73 69 
Parents’/family home 6 6 5 - - 7 9 6 7 - - 
Boarding house/hostel 6 9 9 4 - 14 7 - 15 9 13 
Shelter/refuge 2 2 2 - - - - 0 - - 0 
No fixed address 15 12 16 8 14 24 18 15 21 10 14 
Other 1 1 2 - - 9 0 - - - - 
Note. ^Includes trade/technical and university qualifications. ~ Up until and including 2019, ‘own home’ included private rental and public 
housing. In 2020, these were separated out. - Values suppressed due to small cell size (n≤5 but not 0). / denotes that this item was not 
















Figure 1: Drug of choice, nationally, 2000-2021 
 
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent endorsed other substances. *p<0.050; **p<0.010; ***p<0.001 for 
2020 versus 2021.  
 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Heroin 63 48 55 57 58 57 48 52 52 52 54 53 54 53 50 52 47 46 41 45 50 40
Methamphetamine 16 25 21 23 20 21 23 21 22 21 16 20 21 23 24 26 29 32 35 33 33 45
Morphine 3 5 6 5 6 5 8 10 10 8 10 9 11 8 10 10 8 9 7 4 4 4




























Figure 2: Drug injected most often in the past month, nationally, 2000-2021 
 
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent endorsed other substances. *p<0.050; **p<0.010; ***p<0.001 for 
2020 versus 2021. 
 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Heroin 58 36 43 40 47 43 27 36 37 43 43 43 42 40 41 41 39 37 37 40 46 34
Methamphetamine 23 36 28 34 26 29 32 26 26 24 19 26 25 26 30 33 39 40 44 45 41 53
Morphine 2 6 17 13 15 12 18 18 19 16 19 16 16 17 16 13 12 12 10 6 5 5




























Figure 3: Weekly or more frequent substance use in the past six months, nationally, 2000-2021  
 
Note. Computed of the entire sample regardless of whether they had used the substance in the past six months. Non-prescribed morphine frequency of use not asked until 2006. Crystal 
methamphetamine frequency of use not asked in 2000-2001. / Not asked. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Heroin 64 44 46 46 49 47 34 42 42 48 46 44 46 43 44 44 41 42 38 43 51 37
Any methamphetamine 26 42 37 39 36 38 42 37 32 32 25 30 33 33 35 38 44 43 50 51 48 58
Non-prescribed morphine 20 23 22 17 19 17 18 17 19 14 13 13 11 8 6 6
Cannabis 65 70 71 67 68 65 68 68 63 63 59 64 60 58 59 57 57 55 54 57 51 54
Crystal methamphetamine 11 19 17 11 20 15 18 11 11 15 20 23 29 33 42 41 47 48 47 57









































Participants were asked about COVID-19 testing, diagnosis and 
vaccination. 







The first COVID-19 diagnosis occurred in Australia on 25 January 2020, with a rapid increase in cases 
throughout March (peak 455 cases 28 March 2020) which declined shortly thereafter (<20 cases per 
day nationally from 20 April 2020). There was a resurgence in cases from late June 2020, largely 
based in Victoria (peak 686 cases 5 August 2020), which subsequently declined from September 
onwards (<20 cases per day from 23 September 2020) (Figure 4). The third wave of cases occurred 
from late June 2021 onwards, largely in NSW (peak 1293 cases 30 August 2021, not including cases 
from 1 September 2021 onwards) and a couple of months later in VIC (peak 86 cases 29 August 
2021, not including cases from 1 September 2021 onwards). The number of cases in other 
jurisdictions during this third wave did not exceed 30 cases per day (as of 31 August 2021).  
As a nation of federated states and territories, public health policy including restrictions on movement 
and gatherings varies by jurisdiction. However, restrictions on gatherings were implemented across 
jurisdictions from early March 2020; by the end of March, Australians could only leave their residence 
for essential reasons. These restrictions were eased across May-June 2020, again with variation 
across jurisdictions (notably, significant restrictions being enforced again in Victoria from July-October 
2020). Restrictions were re-introduced in Victoria from 27 May to 10 June, 2021, and in NSW from 26 
June 2021 onwards, with other jurisdictions (VIC, QLD, SA and ACT) introducing restrictions shortly 
thereafter. Lockdowns of less than one-week were also introduced during the interviewing period, for 
example in the NT and WA, however these are not displayed in Figure 4. 
Notably, most of the 2021 IDRS surveys occurred before the most recent wave of cases and 
subsequent introduction of restrictions. Specifically, 58% (n=511) of all interviews were 
conducted before 26 June 2021 (when restrictions were first introduced in NSW).  
Figure 4: Timeline of COVID-19 in Australia and IDRS data collection period, 2020-2021 
 
Note. Data obtained from http://www.covid19data.com.au. Only lockdowns of >7 days and affecting at least an entire city are displayed. 
*national stay-at-home orders began lifting dependent on jurisdiction from May 1 2020. ^NSW lockdown 26 June 2021 onwards; VIC 
lockdowns 14 July-27 July 2021 and 5 August 2021 onwards; SA lockdown 20 July-27 July; Southeast QLD lockdown 31 July-8 August 
2021; ACT lockdown 12 August 2021 onwards. 






COVID-19 Testing and Diagnosis 
In 2021, nearly half (46%) of the IDRS sample had been tested for SARS-COV-2 by the time of 
interview (20% in 2020), and no participants had been diagnosed with the virus. Eighteen per cent of 
participants reported that they had quarantined for 14 or more days due to a possible exposure since 
January 2020; 4% in the past month, 9% two-six months ago, and 5% 7-12 months ago. One in ten 
participants (10%) had received at least one dose of the COVID-19 vaccine at the time of interview. 
When asked how worried participants currently were of contracting COVID-19, 28% reported some 
level of concern: 16% responded that they were ‘slightly’ concerned, 8% reported ‘moderately’, 3% 
reported ‘very’ and 1% reported being ‘extremely’ concerned (Figure 5). Further, over two-thirds (68%) 
of participants reported that they would be concerned about their health if they did contract COVID-
19, with 15% reporting that they would be ‘slightly’ concerned, 16% reporting ‘moderately’, 22% 
reporting ‘very’ and 15% reporting that they would be ‘extremely’ concerned.  
 
Figure 5: Current concern related to contracting COVID-19, nationally, 2020-2021 
 
Note. The response ‘Don’t know’ was excluded from analysis.  
 
Not at all Slightly Moderately Very Extremely
2020 51 23 15 7 4





































Participants were asked about their recent (past six month) use of 
heroin and of homebake heroin. Participants typically describe heroin 
as white/off-white rock, brown/beige rock or white/off-white powder. 
Homebake is a form of heroin made from pharmaceutical products and 
involves the extraction of diamorphine from pharmaceutical opioids 
such as codeine and morphine.   






Patterns of Consumption 
Recent Use (past 6 months) 
Despite some fluctuation over the years, recent use of any heroin has been decreasing over time. In 
2021, recent use of heroin reached the lowest percentage since monitoring began (50%) and was 
significantly lower compared to 2020 (63% in 2020; p<0.001) (Figure 6). Consistent with previous 
years, marked differences across jurisdictions can be observed, ranging from less than one in twenty 
participants in NT to almost four-fifths of participants in the ACT reporting recent use. SA recorded 
the greatest significant decrease in 2021 relative to 2020 (23% versus 47%, respectively; p=0.001), 
followed by QLD (43% in 2021 versus 64% in 2020; p=0.003) and VIC (76% in 2021 versus 86% in 
2020, p=0.049), whilst use in the other jurisdictions remained stable (Table 2). 
Frequency of Use 
Median frequency of use nationally was equivalent to three days a week in the past six months (2021; 
median 72 days, IQR=24-180), a significant decrease from four days a week in 2020 (96 days, 
IQR=30-180; p=0.008) (Figure 6). Weekly or more frequent use also declined, from 80% of people 
who reported recent use in 2020 to 75% in 2021 (p=0.045), and daily use declined from 36% of people 
who reported recent use in 2020 to 28% in 2021 (p=0.015). No one reported daily use in the NT 
sample, whereas a significant decrease in the ACT sample was observed in 2021 relative 2020 (26% 
of people who reported recent use versus 45%, respectively; p=0.018). The VIC sample had the 
highest per cent of participants reporting daily heroin use (39% of people who reported recent use).  
Routes of Administration 
Injecting remained the most common route of administration among people who consumed heroin, 
with 100% reporting heroin injection in the past six months (100% in 2020; p=0.588). Participants who 
reported injecting did so on a median of 72 days (IQR=24-180), down from 96 days in 2020 (IQR=30-
180; p=0.003). Few participants reported smoking (5%; 7% in 2020; p=0.222) and snorting (2%; 1% 
in 2020; p=0.878) heroin.  
Quantity 
Of those who reported recent use and responded (n=429), the median amount of heroin used per day 
in the last six months was 0.20 grams (IQR=0.10-0.40; 0.20 grams in 2020; IQR=0.10-0.50; p=0.026). 
The median maximum amount of heroin used per day in the last six months was 0.40 grams 















Figure 6: Past six month use and frequency of use of heroin, nationally, 2000-2021 




2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 79 66 68 65 69 66 56 59 60 64 64 62 60 60 60 58 58 57 54 55 63 50















































Table 2: Past six month use of heroin, by jurisdiction, 2000–2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 95 92 97 38 73 80 56 86 
2001 96 83 90 24 65 55 36 62 
2002 96 89 94 21 48 64 22 81 
2003 97 88 90 26 55 63 16 64 
2004 95 91 86 19 60 69 34 79 
2005 88 86 89 19 61 69 24 64 
2006 81 71 76 9 60 53 12 63 
2007 88 72 85 - 67 57 7 65 
2008 83 86 85 - 51 59 14 74 
2009 94 78 79 12 72 71 13 75 
2010 92 78 85 8 64 69 5 81 
2011 87 79 81 19 57 79 9 65 
2012 89 74 84 9 52 80 11 65 
2013 83 75 83 10 41 75 17 72 
2014 85 75 83 13 43 79 7 66 
2015 91 79 74 - 49 75 14 50 
2016 86 70 77 7 37 78 7 58 
2017 80 74 80 15 52 66 13 55 
2018 83 75 83 8 35 67 9 45 
2019 82 77 85 15 28 62 - 63 
2020 78 85 86 24 47 69 - 64 
2021 75 78 76* 11 23** 61 - 43** 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
Price, Perceived Purity and Perceived Availability 
Price 
In 2021, the reported median price for heroin nationally was $300 for one gram (IQR=250-400; n=73), 
a significant decrease from $400 in 2020 (IQR=250-550; n=95; p=0.004). The median last price per 
cap has remained stable over the years, with a median price of $50 per cap in 2021 (IQR=50-74; 
n=38) and 2020 (IQR=50-100; n=25; p=0.399) (Figure 7). Additionally, participants reported a median 
price of $80 per point (0.10 of a gram; IQR=50-100; n=225), a significant increase from $70 in 2020 
(IQR=50-100; n=259; p=0.026). 
Perceived Purity 
Among those who were able to comment (n=421 in 2021), there was a significant change in the 
perceived purity of heroin in 2021 relative to 2020 (p<0.001). Specifically, there was an increase in 
participants reporting the perceived purity of heroin to be ‘high’ (24%; 14% in 2020) and fewer reported 
‘low’ (28%; 44% in 2020) (Figure 8).  
Perceived Availability 
Among those who were able to comment (n=435 in 2021), there was a significant change in the 
perceived availability of heroin in 2021 relative to 2020 (p=0.024). While participants’ reports of heroin 
being ‘easy’ to obtain remained similar at 44% in 2021 (42% in 2020), there was an increase in those 
perceiving heroin to be ‘very easy’ to obtain in 2021 relative to 2020 (40% versus 35% in 2020) (Figure 
9).  
 






Figure 7: Median price of heroin per cap, point and gram, nationally, 2000-2021 
Note. Among those who commented. Price for a gram of heroin was not collected in 2000. Between 2009-2017 a cap was referred to as cap/point and in 2018 these measures were separated 








2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Cap 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50
Point 50 50 50 50 50 50 50 50 50 50 50 70 80

























Figure 8: Current perceived purity of heroin, nationally, 2000-2021 
 















































Fluctuates - 8 10 9 13 11 8 10 10 14 13 12 13 11 13 14 13 14 14 17 17 15
Low 29 63 43 40 35 43 60 47 41 39 44 42 40 50 46 42 33 31 33 27 44 28
Medium 49 21 37 39 38 37 25 34 40 37 31 35 34 32 30 34 34 34 34 31 25 33
































Figure 9: Current perceived availability of heroin, nationally, 2000-2021 
 
















































Very difficult 2 7 1 2 1 3 5 1 1 2 3 3 2 5 2 2 1 2 1 2 5 2
Difficult 6 21 14 11 11 12 21 12 14 9 11 11 11 13 10 10 8 8 10 9 19 14
Easy 21 39 38 42 34 36 40 46 46 37 34 38 36 38 39 39 38 37 34 35 42 44












































Participants were asked about their recent (past six month) use of 
various forms of methamphetamine, including powder (white particles, 
described as speed), base (wet, oily powder) and crystal (clear, ice-
like crystals). 






Patterns of Consumption (any methamphetamine) 
Recent Use (past 6 months) 
Recent use of any methamphetamine (powder, base and crystal) peaked in 2003 (89%), before 
declining to 60% in 2010. In the following years, the per cent of participants reporting recent use of 
any methamphetamine has been gradually increasing. Indeed, there was a significant increase in the 
per cent of participants reporting any methamphetamine use in 2021 (80%) compared to 2020 (72%), 
(p<0.001), returning to levels observed in 2019 and 2018 (Figure 10).  
In all jurisdictions, at least 70% of participants reported recent use of methamphetamine in 2021, 
ranging from 74% in the NSW sample to 89% in the TAS sample. A significant increase between 2020 
and 2021 was observed in QLD (63% versus 79% respectively; p=0.020) and VIC (66% versus 79% 
respectively; p=0.012) (Table 3).   
Frequency of Use 
Frequency of use significantly increased from a median of 48 days (IQR=12-108) in 2020 to a median 
of 72 days in 2021 (IQR=20-120; p=0.008) (Figure 11). The per cent of people who had recently used 
methamphetamine reporting weekly or more frequent use also significantly increased from 68% in 
2020 to 74% in 2021 (p=0.012). Significant increases in daily use among people who had recently 
used methamphetamine were observed in the NT (26%; 11% in 2020; p=0.044) and VIC (19%; 8% 
in 2020; p=0.021) samples relative to 2020.  
Forms of Methamphetamine 
The forms of methamphetamine used by participants have shifted over time, with use of powder and 
base methamphetamine decreasing and use of crystal methamphetamine increasing (Figure 10). In 
2021, crystal methamphetamine continued to be the most reported form of methamphetamine (78%; 
71% in 2020; p=0.001), followed by powder (12%; 20% in 2020; p<0.001) and base 



















Figure 10: Past six month use of any methamphetamine and of methamphetamine powder, base, and crystal, nationally, 2000-2021 
Note. #Base asked separately from 2001 onwards (/ Not asked). ‘Any methamphetamine’ includes crystal, powder, base and liquid methamphetamine combined from 2000-2018, and crystal, powder 






2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Powder 58 62 56 55 53 60 56 55 48 48 41 44 40 34 30 25 20 20 20 23 20 12
Base# 40 39 35 38 39 38 32 22 28 21 21 18 13 12 10 8 10 7 9 8 3
Crystal 15 53 35 54 52 43 57 46 49 37 39 45 54 55 61 67 73 68 75 75 71 78
































Figure 11: Frequency of use of any methamphetamine and of methamphetamine powder, base, and crystal, nationally, 2000-2021 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 80 days to improve visibility of trends. 
Collection of frequency of use data for base and crystal commenced in 2002 (/ Not asked). Frequency of use data was not collected in 2020 for base methamphetamine. *p<0.050; **p<0.010; 





2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Powder 18 13 10 10 9 10 12 12 10 12 10 10 10 10 6 11 6 6 5 10 12 12
Base 12 10 10 10 7 10 6 10 10 6 6 6 6 7 8 5 5 6 6
Crystal 10 12 7 6 10 10 12 7 7 10 12 12 20 20 20 30 46 48 48 71

























Table 3: Past six month use of any methamphetamine, by jurisdiction, 2000–2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 40 68 53 83 52 85 74 71 
2001 51 82 76 85 81 92 70 83 
2002 48 70 73 84 85 85 72 81 
2003 53 71 79 88 72 90 71 89 
2004 56 81 71 91 71 85 70 81 
2005 58 73 79 95 78 75 72 78 
2006 72 92 81 83 78 86 64 82 
2007 62 83 74 88 74 70 68 78 
2008 74 74 68 74 69 74 57 59 
2009 57 75 70 80 61 63 55 70 
2010 57 59 60 70 74 64 36 59 
2011 60 73 65 77 66 64 55 71 
2012 72 77 67 77 79 72 48 53 
2013 75 66 61 74 75 72 43 58 
2014 75 76 77 70 75 66 37 72 
2015 66 81 74 72 76 71 67 67 
2016 77 83 73 75 77 65 71 70 
2017 69 80 66 69 76 70 66 74 
2018 76 85 78 79 83 67 75 72 
2019 76 79 70 81 90 79 90 68 
2020 77 65 66 77 81 73 83 63 
2021 74 75 79* 89 88 82 76 79* 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.






Patterns of Consumption (by form) 
Methamphetamine Powder   
Recent Use (past 6 months): Nationally, the 
use of methamphetamine powder has 
decreased over time. In 2021, recent use 
declined to 12%, the lowest percentage of use 
since monitoring began (20% in 2020; 
p<0.001) (Figure 10). Most jurisdictions have 
reflected this trend, with some fluctuation over 
time. A significant decrease in recent use of 
methamphetamine powder was observed in 
TAS (16%; 43% in 2020; p<0.001), WA (9%; 
36% in 2020; p<0.001) and NSW (n≤5; 11% in 
2020; p=0.009) (Table 4).  
Frequency of Use: Nationally, frequency of 
use remained stable in 2021 at a median of 12 
days (IQR=3-72; 12 days in 2020; IQR=3-60; 
p=0.473) (Figure 11). In 2021, just under half 
(47%) of those who had recently used 
methamphetamine powder reported weekly or 
more frequent use, stable from 43% in 2020 
(p=0.640).  
Routes of Administration: Most (95%) 
people who had recently used 
methamphetamine powder reported injecting 
powder in the past six months (93% in 2020; 
p=0.456) and reported doing so on a median of 
12 days (IQR=3-72), stable relative to 2020 (12 
days; IQR=3-71; p=0.831). Over a quarter 
(26%) reported smoking powder 
methamphetamine (21% in 2020; p=0.399).  
Quantity: Of those who reported recent use 
and responded (n=101), the median amount of 
powder used on a typical day in the past six 
months was 0.20 grams (IQR=0.10-0.40; 0.20 
grams in 2020; IQR=0.10-0.40; p=0.725). The 
median maximum amount of powder used per 
day in the last six months was 0.40 grams 
(IQR=0.20-1.00; n=98; maximum quantity of 
powder was not collected in 2020).  
Methamphetamine Base 
Recent Use (past 6 months): Base has 
typically been the least commonly used form of 
methamphetamine since monitoring 
commenced in 2001. Though some 
fluctuations have occurred, recent base use 
has gradually declined overtime. Indeed, the 
per cent of participants reporting recent use of 
base significantly declined to 3% in 2021 (8% 
in 2020; p<0.001), largely driven by a decline 
in the SA sample. No one reported recent use 
in VIC and WA, whereas 8% of participants 
from QLD and the ACT samples reported 
recent use.   
Frequency of Use: Frequency of use 
remained relatively low in 2021, at a median of 
6 days (IQR=2-30; n=25; frequency data not 
collected in 2020).  
Routes of Administration: Injecting was 
reported to be the most common route of 
administration amongst people who had used 
methamphetamine powder (100%; 97% in 
2020), with few participants reporting smoking 
(n≤5; n≤5 in 2020). Due to small numbers 
reporting recent use, significance testing for 
routes of administration were not undertaken. 
Quantity: Of those who reported recent use 
and responded (n=19), the median amount of 
base used on a typical day in the past six 
months was 0.20 grams (IQR=0.10-0.50). The 
median maximum amount of base used per 
day in the last six months was 0.50 grams 
(IQR=0.20-0.60; n=21; average and maximum 
quantity of base were not collected in 2020).   
Methamphetamine Crystal 
Recent Use (past 6 months): Reports of 
recent use of crystal methamphetamine have 
been increasing since 2009 (Figure 10), 
surpassing powder methamphetamine from 
2012 onwards. In 2021, recent use significantly 
increased to 78% of the national sample (71% 
in 2020; p=0.001), indicating the highest per 
cent of recent use since monitoring 
commenced in 2000. At the jurisdictional level, 
recent use ranged from 74% in NSW, ACT and 
NT samples, to 85% in the TAS sample in 2021 
(Table 6). A significant increase in the per cent 
reporting use between 2020 and 2021 was 
observed in QLD (78%; 63% in 2020, p=0.030) 






and VIC (78%; 64% in 2020; p=0.008) 
samples.    
Frequency of Use: Median days of use 
significantly increased from 48 days in 2020 
(IQR=12-100) to 71 days in 2021 (IQR=20-110; 
p=0.002) (Figure 11). Among those who had 
recently used crystal methamphetamine, 
frequency of use on a weekly or more basis 
also significantly increased in 2021 (73%; 66% 
in 2020; p=0.006), though daily use remained 
stable (18%; 16% in 2020; p=0.338).   
Routes of Administration: Consistent with 
previous years, the most common route of 
administration was injecting (97%; 95% in 
2020; p=0.072), followed by smoking (37%; 
35% in 2020; p=0.529). Participants who 
reported injecting did so on a median of 60 
days (IQR= 20-96), a significant increase from 
45 days in 2020 (IQR= 12-96; p=0.008). There 
was large jurisdictional variation in the per cent 
of participants nominating smoking as a route 
of administration. The VIC sample (57%) had 
the highest per cent of people who had recently 
used crystal methamphetamine nominating 
smoking as a route of administration, whereas 
few participants (n≤5) reported smoking in the 
NT sample. 
Quantity: Of those who reported recent use 
and responded (n=675), the median amount of 
crystal used on an average day of consumption 
in the past six months was 0.20 grams 
(IQR=0.10-0.20; 0.10 grams in 2020; 
IQR=0.10-0.20; p=0.493). The median 
maximum amount of crystal used per day in the 
last six months was 0.30 grams (IQR=0.20-
0.50; n=666; maximum quantity of crystal 
recently used was not collected in 2020).  
 
Table 4: Past six month use of powder methamphetamine, by jurisdiction, 2000-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 32 63 49 77 51 81 70 58 
2001 42 63 74 45 47 87 63 80 
2002 39 51 70 35 56 77 67 55 
2003 31 48 70 51 53 71 60 58 
2004 35 41 65 60 44 61 60 61 
2005 38 59 75 76 39 61 69 65 
2006 49 58 71 54 39 66 57 54 
2007 35 55 65 63 42 61 58 62 
2008 38 37 64 61 34 61 50 35 
2009 33 46 65 56 33 54 50 46 
2010 29 48 53 56 29 51 25 41 
2011 30 46 49 67 36 43 43 40 
2012 17 42 39 70 34 45 46 30 
2013 14 29 23 61 40 48 31 37 
2014 17 36 25 50 34 39 16 31 
2015 13 15 18 49 32 34 25 27 
2016 17 18 9 33 19 18 24 27 
2017 10 20 15 30 18 16 19 34 
2018 11 23 16 22 31 12 17 34 
2019 13 27 11 35 44 26 15 20 
2020 11 13 10 43 35 36 - 19 
2021 -** 13 7 16*** 34 9*** - 19 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021.
  






Table 5: Past six month use of base methamphetamine, by jurisdiction, 2001-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2001 23 36 32 52 59 56 18 75 
2002 23 30 20 74 65 56 21 42 
2003 32 13 18 46 51 40 30 50 
2004 31 25 11 72 46 45 26 60 
2005 38 28 13 79 61 54 16 40 
2006 43 32 15 55 52 37 25 53 
2007 41 32 8 48 42 22 20 48 
2008 33 18 5 25 37 13 10 34 
2009 36 21 13 55 31 12 16 41 
2010 29 18 3 40 43 8 6 30 
2011 17 17 11 39 35 6 12 37 
2012 15 15 11 43 32 6 7 21 
2013 12 6 3 17 31 11 7 22 
2014 12 - 3 19 30 8 - 22 
2015 6 10 4 9 26 - - 20 
2016 11 5 0 - 24 - 6 14 
2017 8 11 3 - 30 7 7 20 
2018 9 8 - - 8 - 10 14 
2019 8 8 - - 24 - - 16 
2020 4 - - 8 28 8 - 10 
2021 - 8 0 - -*** 0* - 8 
Note. Base asked separately from 2001 onwards. - Values suppressed due to small cell size (n≤5 but not 0).  *p<0.050; **p<0.010; 
***p<0.001 for 2020 versus 2021. 
 
Table 6: Past six month use of crystal methamphetamine, by jurisdiction, 2000-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 14 17 9 6 11 51 6 13 
2001 29 72 52 56 58 85 24 75 
2002 25 34 26 20 56 74 20 39 
2003 38 65 50 69 48 80 34 60 
2004 45 73 41 52 48 83 32 51 
2005 38 62 29 50 46 68 21 36 
2006 57 88 53 56 49 76 29 55 
2007 50 80 43 38 41 56 29 39 
2008 69 68 39 32 49 61 28 40 
2009 46 57 32 26 30 43 15 46 
2010 48 48 36 20 60 40 18 37 
2011 53 57 53 26 44 46 28 50 
2012 68 66 59 43 56 64 26 44 
2013 74 61 55 45 57 59 30 50 
2014 74 72 75 54 60 53 26 58 
2015 65 79 71 59 70 64 60 62 
2016 77 78 73 73 73 75 62 69 
2017 69 79 63 65 72 69 60 69 
2018 76 85 77 76 79 64 74 70 
2019 74 77 68 76 89 75 87 65 
2020 75 63 64 77 80 69 83 63 
2021 74 74 78** 85 83 80 74 78* 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 






Price, Perceived Purity and 
Perceived Availability 
Methamphetamine Powder  
Questions pertaining to the price, perceived 
purity and availability of methamphetamine 
powder were not asked of participants in 2020, 
meaning that significance testing between 
2021 and 2020 figures cannot be undertaken. 
Price: The median price for a point (0.10 of a 
gram) of methamphetamine powder has 
remained stable at $50 (IQR=50-80; n=69) 
across the duration of monitoring (Figure 12).  
In contrast, the median price of one gram has 
fluctuated over time, with a gram reported to be 
$225 in 2021 (IQR=156-388; n=10).  
Perceived Purity: Perceptions regarding the 
perceived purity of powder methamphetamine 
were mixed. Among those who commented in 
2021 (n=107), purity was most commonly 
perceived as ‘medium’ (36%), with almost 
equal percentages reporting that purity was 
‘high’ (25%) or ‘low’ (24%) (Figure 14).  
Perceived Availability: Of those who 
commented in 2021 (n=109), just under two-
thirds of participants reported 
methamphetamine powder to be ‘very easy’ 
(32%) or ‘easy’ (32%) to obtain. The remaining 
one-third perceived it as ‘difficult’ (23%) or ‘very 
difficult’ (13%) to obtain (Figure 16).  
Methamphetamine Base  
Questions pertaining to the price, perceived 
purity and availability of methamphetamine 
base were not asked of participants in 2021 or 
2020. For historical information, please refer to 
the 2019 IDRS National Report.  
Methamphetamine Crystal  
Price: The median price for a point (0.10 of a 
gram) of crystal significantly decreased in 2021 
($50; IQR=50-100; n=438; $100 in 2020; 
IQR=60-150; n=435; p<0.001), returning to the 
same median price observed from 2016-2019. 
Across the years, the median price of a gram 
of crystal has ranged between $250 and $600. 
Relative to 2020, the median price for a gram 
of crystal significantly decreased to $400 
(IQR=300-500; n=67) in 2021 ($500 in 2020; 
IQR=363-700; n=51; p=0.003) (Figure 13).  
Perceived Purity: Among those that were able 
to comment (n=623 in 2021), there was a 
significant change in the perceived purity of 
methamphetamine crystal (p<0.001). Twenty-
eight per cent of participants, nationally, 
perceived the purity of crystal to be ‘high’, an 
increase relative to 2020 (14%). In contrast, 
one-fifth (21%) perceived purity to be ‘low’, a 
decrease from 40% in 2020 (Figure 15). 
Perceived Availability: Of those who 
commented (n=641 in 2021), the perceived 
availability of methamphetamine crystal 
significantly changed between 2020 to 2021 
(p<0.001). Specifically, there was a decrease 
in the percentage of participants who reported 
crystal methamphetamine to be ‘difficult’ to 




















Figure 12: Median price of powder methamphetamine per point and gram, nationally, 2002-2021 
 
Note. Among those who commented. Price data for powder not collected in 2020 (/ Not asked), therefore statistical significance testing has 




Figure 13: Median price of methamphetamine crystal per point and gram, nationally, 2001-2021 
 
 
Note. Among those who commented. No data available for gram in 2001 (/ Not asked). The error bars represent the IQR. *p<0.050; 
**p<0.010; ***p<0.001 for 2020 versus 2021. 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Point 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50

















2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Point 50 50 50 50 50 50 50 50 50 50 100 100 100 100 80 50 50 50 50 100 50




























Figure 14: Current perceived purity of powder methamphetamine, nationally, 2002-2021 
 
 
Note. Methamphetamine asked separately for the three different forms from 2002 onwards. The response ‘Don’t know’ was excluded from analysis. Data on perceived purity of powder not collected 











































Fluctuates 15 15 16 14 14 19 15 14 13 16 18 14 15 14 13 12 14 13 15
Low 35 28 31 36 41 36 45 47 40 33 31 26 20 24 19 28 28 24 24
Medium 31 31 34 32 29 32 28 25 33 31 29 37 37 34 38 37 37 37 36































Figure 15: Current perceived purity of crystal methamphetamine, nationally, 2002-2021 
 
 


















































Fluctuates 7 6 8 6 14 11 11 14 12 16 15 13 17 18 14 19 15 18 19 21
Low 6 8 9 9 8 19 15 28 16 14 13 13 12 15 16 18 19 16 40 21
Medium 25 22 27 25 28 29 32 26 28 31 30 30 31 27 32 33 30 31 27 30
































Figure 16: Current perceived availability of powder methamphetamine, nationally, 2002-2021 
 
 
Note. Methamphetamine asked separately for the three different forms from 2002 onwards. The response ‘Don’t know’ was excluded from analysis. Data on perceived availability of powder not 







































Very difficult 2 3 2 3 4 2 3 2 3 4 1 2 2 4 10 8 10 7 13
Difficult 11 14 14 14 12 13 18 16 18 16 11 15 14 19 15 20 9 16 23
Easy 36 35 45 39 43 45 50 44 38 45 44 45 51 37 36 39 32 27 32































Figure 17: Current perceived availability of crystal methamphetamine, nationally, 2002-2021 
 
  










































Very difficult 11 3 4 6 3 3 2 9 5 2 2 0 0 1 1 0 1 0 19 2
Difficult 26 14 20 27 15 15 15 26 19 15 14 12 9 4 4 5 6 5 33 12
Easy 27 35 44 40 43 39 46 33 41 43 38 46 42 39 38 39 30 31 31 40








































Participants were asked about their recent (past six month) use of 
various forms of cocaine. Cocaine hydrochloride, a salt derived from 
the coca plant, is the most common form of cocaine available in 
Australia. ‘Crack’ cocaine is a form of freebase cocaine (hydrochloride 
removed), which is particularly pure. ‘Crack’ is most prevalent in North 
America and infrequently encountered in Australia. 






Patterns of Consumption 
Recent Use (past 6 months) 
The per cent reporting recent use of cocaine has generally decreased over the period of monitoring. 
In 2021, 15% of the IDRS sample reported cocaine use in the past six months, stable from 17% in 
2020 (p=0.143) (Figure 18). The per cent reporting use in 2021 varied across jurisdictions, ranging 
from five or less participants in the NT sample to 18% of the QLD sample. Overall, the per cent 
reporting recent cocaine use has remained relatively stable in each of the jurisdictions over time 
except for a substantial decrease in NSW (Table 7). 
Frequency of Use 
Median frequency of use at the national level has varied between two and eight days, with a median 
of three days (IQR=1-5; n=130) observed in 2021, stable from 2020 (3 days; IQR=1-6; p=0.897) 
(Figure 18). Of those who had recently used cocaine and commented (n=130), almost one-tenth (8%) 
reported weekly or more frequent use, consistent with 2020 (8%; p=0.977).  
Routes of Administration 
No statistically significant changes in route of administration were observed between 2020 and 2021; 
snorting proved to be the most common route amongst those reporting recent use (58%; 55% in 2020; 
p=0.720), followed by injecting (50%; 52% in 2020; p=0.722). A smaller per cent reported smoking 
(5%; 7% in 2020; p=0.455) and swallowing (n≤5; 4% in 2020) cocaine. 
Quantity 
Of those who reported recent use and responded (n=104), the median amount of cocaine used on an 
average day of consumption in the six months preceding interview was 0.30 grams (IQR=0.10-1.00; 




















Figure 18: Past six month use and frequency of use of cocaine, nationally, 2000-2021 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. 




2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 24 35 27 18 16 22 20 22 20 21 18 17 15 16 12 13 11 13 14 13 17 15














































Table 7: Past six month use of cocaine, by jurisdiction, 2000-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 63 15 13 6 20 22 18 13 
2001 84 40 28 8 27 32 13 28 
2002 79 18 17 12 26 17 10 15 
2003 53 13 13 9 13 10 - 16 
2004 47 10 10 - 6 15 10 10 
2005 60 20 15 8 16 19 10 11 
2006 67 8 19 12 8 10 8 9 
2007 63 18 22 - 7 16 9 15 
2008 58 18 24 - - 15 - 13 
2009 61 22 15 - 10 12 12 15 
2010 57 6 14 - 12 15 - 13 
2011 47 8 17 7 12 10 - 13 
2012 44 16 9 11 7 15 - - 
2013 41 16 11 - 9 15 7 11 
2014 32 15 10 8 7 7 - 9 
2015 34 12 9 - 13 11 - 8 
2016 25 8 10 6 6 10 - 9 
2017 21 18 12 11 10 10 9 9 
2018 26 14 15 11 10 12 6 9 
2019 21 15 10 6 16 12 9 10 
2020 23 19 17 16 14 18 - 19 
2021   15 16 18 16 16 17 - 12 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Price, Perceived Purity and Perceived Availability 
Questions pertaining to the price, perceived purity and availability of cocaine were not asked of 
participants in 2020, meaning that significance testing between 2021 and 2020 figures cannot be 
undertaken. 
Price 
The median price for one gram of cocaine was reported to be $350 (n=37; IQR=300-400) and $90 for 
a point/cap (n=9; IQR=50-100) in 2021. The median price for one gram of cocaine has fluctuated 
considerably since monitoring first commenced (Figure 19).  
Perceived Purity 
Of those who were able to comment in 2021 (n=64), almost equal percentages perceived cocaine to 
be of ‘high’ (33%) or ‘medium’ (30%) purity (Figure 20).  
Perceived Availability 
Amongst those able to comment in 2021 (n=64), the largest per cent reported cocaine to be ‘easy’ to 
obtain in 2021 (45%), with a further 23% reporting it to be ‘very easy’ to obtain (Figure 21). These 











Figure 19: Median price of cocaine per cap/point and gram, nationally, 2000-2021 
 
Note. Among those who commented. The error bars represent IQR. Price data not collected in 2020 (/ Not asked), therefore statistical 





































2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Cap/Point 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 90























Figure 20: Current perceived purity of cocaine, nationally, 2000-2021 
  













































Fluctuates 0 10 3 6 6 6 13 9 5 11 13 14 7 9 12 8 10 9 9 10 13
Low 27 16 43 43 32 26 24 23 31 15 24 32 22 27 26 26 31 22 33 22 25
Medium 46 43 31 34 35 40 36 43 35 41 32 32 49 36 33 39 31 24 27 38 30


















































































Very difficult 10 3 7 16 10 11 7 8 6 2 7 5 10 3 4 5 5 6 7 11 9
Difficult 28 17 22 30 30 28 25 26 22 18 30 27 25 27 25 21 34 35 29 27 22
Easy 29 32 38 29 33 25 40 37 54 46 35 43 45 42 38 32 39 31 42 38 45










































Participants were asked about their recent (past six month) use of 
indoor-cultivated cannabis via a hydroponic system (‘hydro’) and 
outdoor-cultivated cannabis (‘bush’), as well as hashish and hash oil.  






Patterns of Consumption 
Recent Use (past 6 months) 
Over the course of monitoring, at least two in three participants nationally have reported recent use 
of cannabis. In 2021, over two-thirds of the national sample reported recent use (67%), stable from 
2020 (67%; p=0.787) (Figure 22). In all jurisdictions, the per cent reporting recent cannabis use has 
declined over time and remained stable between 2021 and 2020 (Table 8).   
Frequency of Use 
In 2021, median frequency of use in the past six months was 180 days (i.e., daily; IQR=45-180), 
similar to 2020 (160 days; IQR=24-180; p=0.150) (Figure 22). Just over half (51%) of those who had 
recently used cannabis reported daily use (48% in 2020; p=0.337).  
Routes of Administration 
Smoking remained the most common route of administration (97%; 97% in 2020; p=0.842). A smaller 
per cent reported inhaling/vaporising (8%; 8% in 2020; p=0.700) and swallowing (5%; 5% in 2020) 
cannabis.  
Quantity 
Of those who reported recent use and commented (n=563), the median typical amount used on the 
last occasion of use was one gram (IQR=1.00-2.00; n=303; 1.00 gram in 2020; IQR=0.80-2.00; 
p=0.052) or 2.5 cones (IQR=2-4; n=204; 2 cones in 2020; IQR=1-4; p=0.423) or one joint (IQR=1-2; 
n=56; 1 joint in 2020; IQR=1-1; p=0.156).  
Forms of Cannabis 
Of those who had used cannabis in the past six months and commented (n=571), 91% reported recent 
use of hydroponic cannabis (89% in 2020; p=0.390), and under two-fifths (37%) reported recent use 
of outdoor-grown ‘bush’ cannabis (39% in 2020; p=0.409). A smaller percentage reported having used 
hashish (4%; 6% in 2020; p=0.111), hash oil (3%; 4% in 2020; p=0.669) and non-prescribed 


















Figure 22: Past six month use and frequency of use of cannabis, nationally, 2000-2021 












2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Used 84 86 86 83 82 82 83 81 77 76 75 79 76 72 73 73 73 73 73 74 67 67













































Table 8: Past six month use of cannabis, by jurisdiction, 2000-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 72 84 85 90 88 90 84 84 
2001 83 85 88 94 85 91 81 82 
2002 80 89 87 91 85 98 83 82 
2003 79 86 88 88 80 81 83 76 
2004 80 85 81 87 83 84 75 75 
2005 80 89 86 87 80 76 79 76 
2006 80 90 83 88 77 80 84 85 
2007 79 83 83 87 81 69 83 84 
2008 80 80 74 86 75 64 78 82 
2009 79 81 79 89 61 72 79 69 
2010 72 81 81 79 66 70 72 77 
2011 81 87 85 78 69 71 71 79 
2012 72 81 85 81 61 79 71 70 
2013 80 75 80 71 61 61 67 67 
2014 77 74 75 82 75 69 62 70 
2015 79 81 76 73 74 60 72 60 
2016 76 69 77 74 73 70 72 64 
2017 79 76 71 73 73 73 59 70 
2018 76 79 70 81 70 77 60 67 
2019 73 79 76 76 79 72 72 65 
2020 64 77 69 72 67 66 60 64 
2021 65 75 66 67 67 69 59 68 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Price, Perceived Potency and Perceived Availability 
Price 
Consistent with previous years, the median price per gram of hydroponic cannabis nationally was $20 
(IQR=20-25; n=184; $20 in 2020; IQR=20-25; n=155; p=0.941), and $20 for bush (IQR=11-20; n=70; 
$20 in 2020; IQR=17-25; n=65; p=0.112). The price per ounce of hydroponic cannabis was $290 in 
2021 (IQR=250-324; n=66), stable from 2020 ($300; IQR=250-350; n=119; p=0.103), whereas the 
price per ounce of bush cannabis decreased significantly in 2021 ($200; IQR=200-250; n=34) 
compared to 2020 ($250; IQR=200-300; n=119; p=0.038) (Figure 23).   
Perceived Potency  
Among those that were able to comment (hydroponic: n=455; bush: n=212 in 2021), there were no 
significant differences in perceived potency of cannabis between 2021 and 2020 (hydroponic: 
p=0.095; bush: p=0.074). Nearly three-fifths (58%) perceived hydroponic cannabis to be of ‘high’ 
potency (49% in 2020) followed by 28% perceiving it to be of ‘medium’ potency (33% in 2020). In 
contrast, the per cent reporting bush to be of ‘high’ potency was 33% in 2021 (32% in 2020), with the 
larger per cent perceiving it to be of ‘medium’ potency (43%; 44% in 2020) (Figure 24). 
Perceived Availability 
There was a significant change in the perceived availability of hydroponic cannabis in 2021 compared 
to 2020 (p<0.001). Specifically, of those that commented in 2021 (n=463), nearly half (49%) perceived 
hydroponic cannabis to be ‘very easy’ to obtain (33% in 2020), followed by almost two-fifths (39%) 
perceiving it to be ‘easy’ to obtain (48% in 2020). In contrast, there were no changes in the perceived 
availability of bush cannabis between 2021 and 2020 (p=0.955). Of those that commented in 2021 






(n=212), over two-fifths (42%) reported that bush cannabis was ‘easy’ to obtain (44% in 2020), 
followed by 36% perceiving it to be ‘very easy’ to obtain (24% in 2020) (Figure 25). 
Figure 23: Median price of hydroponic (a) and bush (b) cannabis per ounce and gram, nationally, 2003-
2021 
(A) Hydroponic cannabis 
 
 
(B) Bush cannabis 
Note. Among those who commented. From 2003 onwards hydroponic and bush cannabis data collected separately. The error bars 
represent the IQR. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Ounce 280 250 280 278 300 300 300 300 300 290 300 300 300 280 280 280 280 300 290



















2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Ounce 200 200 200 200 200 200 250 250 220 200 240 220 230 250 250 200 200 250 200

























Figure 24: Current perceived potency of hydroponic (a) and bush (b) cannabis, nationally, 2004-2021 









































Fluctuates 7 7 6 7 7 7 7 9 9 9 10 11 9 9 10 9 14 11
Low 3 3 4 3 4 4 4 4 3 4 3 5 4 4 5 3 3 3
Medium 27 29 26 30 28 31 32 30 29 30 32 32 31 33 29 29 33 28































(B) Bush cannabis 
 









































Fluctuates 10 9 7 9 7 5 7 6 4 10 14 6 4 6 8 9 10 8
Low 17 18 13 22 21 18 16 12 24 9 11 15 10 12 19 16 14 16
Medium 51 54 59 52 50 54 52 60 52 54 54 47 61 52 41 48 44 43































Figure 25: Current perceived availability of hydroponic (a) and bush (b) cannabis, nationally, 2004-2021 









































Very difficult 1 1 1 2 1 1 1 1 0 1 0 0 1 1 0 1 3 2
Difficult 8 6 7 9 10 9 8 7 8 7 9 7 8 8 11 12 15 10
Easy 35 35 42 37 44 42 38 39 40 40 40 37 43 38 40 36 48 39
































(B) Bush cannabis 
 











































Very difficult 3 3 2 3 4 3 2 3 2 3 2 4 4 3 2 3 6 4
Difficult 19 19 22 30 24 23 19 21 17 25 26 21 19 22 21 19 25 18
Easy 43 35 48 40 46 36 38 43 46 47 43 42 45 38 40 37 44 42















































The following section describes recent (past six month) use of 
pharmaceutical opioids amongst the sample. Terminology throughout 
this chapter refers to prescribed use: use of pharmaceutical opioids 
obtained by a prescription in the person’s name; non-prescribed 
use: use of pharmaceutical opioids obtained from a prescription in 
someone else’s name; and any use: use of pharmaceutical opioids 
obtained through either of the above means. Contact the Drug Trends 
team (drugtrends@unsw.edu.au) for information on price and 
perceived availability of non-prescribed pharmaceutical opioids. 
 







Any Recent Use (past 6 months): Methadone use (including liquid and tablets) has generally ranged 
between one-third and half of participants reporting any recent use over the course of monitoring. In 
2021, 35% of participants reported recent use of any methadone (prescribed and non-prescribed), a 
significant decrease from 43% in 2020 (p=0.002) (Figure 26). The per cent reporting any non-
prescribed use has steadily been declining since 2015 but remained stable in 2021 (13%). Indeed, 
methadone use historically has largely consisted of prescribed use (25% in 2021; 34% in 2020; 
p<0.001), with the per cent reporting non-prescribed use peaking at 32% in 2008 and declining to 
13% nationally in 2020 and 2021, the lowest percentage reported over the period of monitoring (Figure 
26). The per cent reporting non-prescribed use varies by jurisdiction, from 32% in the TAS sample to 
5% in the VIC sample (Table 9). 
Frequency of Use: Frequency of non-prescribed methadone syrup use in the past six months 
remained stable in 2021 (10 days; IQR=2-35; 5 days in 2020; IQR=2-30; p=0.188) (Figure 26).  
Recent Injection: Of those who had recently use methadone syrup or tablets (n=313), nearly two-
fifths (37%) of participants reported recently injecting methadone, a significant increase relative to 
2020 (26%; p=0.003). Participants in 2021 reported injecting methadone on a median of 24 days 
























Figure 26: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed methadone, nationally, 2000-2021 
Note. Includes methadone syrup and tablets except where otherwise specified. Non-prescribed use not distinguished in 2000-2002 (/ Not asked). Median days computed among those who reported 




2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 45 48 44 49 50 52 49 49 52 46 50 51 46 48 46 41 39 37 42 37 43 35
% Non-Prescribed Use 29 30 28 30 31 32 27 25 26 26 24 24 19 17 16 16 15 13 13











































Table 9: Past six month non-prescribed use of methadone, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 20 27 13 76 33 18 39 18 
2004 29 30 11 75 19 20 35 28 
2005 19 34 11 60 27 27 41 22 
2006 28 39 11 63 28 32 33 20 
2007 24 34 21 66 27 31 33 20 
2008 27 35 21 70 17 19 45 27 
2009 36 26 20 68 10 11 32 11 
2010 27 25 19 58 17 13 27 15 
2011 25 25 22 53 15 27 30 16 
2012 26 27 21 47 14 31 27 12 
2013 29 29 12 51 20 24 13 16 
2014 29 27 21 51 9 20 16 17 
2015 25 16 17 36 11 14 17 14 
2016 21 12 13 40 6 13 14 19 
2017 19 13 7 39 6 - 18 19 
2018 20 13 11 42 - 9 8 18 
2019 22 15 7 29 8 - 13 19 
2020 17 7 10 26 9 11 - 20 
2021 19 14 5 32 7 6 10 13 
Note. Includes methadone syrup and tablets. - Values suppressed due to small cell size (n≤5 but not 0). From 2000-2002, the IDRS did not 
distinguish between prescribed and non-prescribed methadone use. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Buprenorphine 
Any Recent Use (past 6 months): The per cent reporting recent buprenorphine tablet use has 
declined from 2006 onwards (Figure 27). In 2021, 9% of the sample reported recent use of any 
buprenorphine in tablet form, stable from 8% in 2020 (p=0.581). Two per cent reported prescribed 
use (3% in 2020; p=0.242), whereas 6% reported non-prescribed use (5% in 2020; p=0.130) (Figure 
27).  
Frequency of Use: Median days of non-prescribed use in 2021 was 5 days (IQR=2-49; 12 days in 
2020; IQR=3-48; p=0.259).   
Recent Injection: Of those who had recently use buprenorphine (n=76), 68% reported recently 
injecting buprenorphine, stable relative to 2020 (62%; p=0.508). Participants in 2021 reported 
injecting buprenorphine on a median of 8 days (IQR=2-72), also stable from 2020 (23 days; IQR=3-













Figure 27: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed buprenorphine, nationally, 2002-2021 
Note. Non-prescribed use not distinguished in 2002 (/ Not asked). Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 40 days to improve visibility of trends. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 21 25 33 35 35 29 26 23 22 21 19 16 18 14 14 14 10 8 8 9
% Non-Prescribed Use 12 16 18 23 18 16 18 16 15 14 12 14 11 10 10 7 5 5 6












































Table 10: Past six month non-prescribed use of buprenorphine, by jurisdiction, 2003-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 5 - 32 - 10 18 13 7 
2004 8 - 35 - 12 23 15 20 
2005 8 15 29 - 14 34 20 20 
2006 19 34 29 6 14 32 14 30 
2007 16 28 26 6 11 19 - 31 
2008 7 25 19 - 12 18 18 25 
2009 18 23 25 12 9 16 - 31 
2010 13 27 21 - 9 18 8 27 
2011 12 21 18 6 8 11 8 33 
2012 13 20 19 6 9 14 10 22 
2013 11 16 9 9 7 10 20 16 
2014 22 12 12 11 - 19 12 19 
2015 9 11 12 13 6 8 10 17 
2016 11 8 4 10 - 9 16 26 
2017 13 14 6 9 7 10 - 25 
2018 - 9 5 11 - 8 - 12 
2019 4 - - - 0 - - 15 
2020 5 0 0 11 - 9 0 14 
2021 5 - - 11 - - - 20 
Note. In 2002, the IDRS interview did not distinguish between prescribed and non-prescribed use. Values suppressed due to small cell size 
(n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Buprenorphine-Naloxone 
Any Recent Use (past 6 months): The per cent reporting any recent buprenorphine-naloxone use 
has remained relatively stable over the past decade. In 2021, 15% of the sample reported recent use 
of any buprenorphine-naloxone, stable from 2020 (18%; p=0.147). Seven per cent reported recent 
prescribed use in 2021, a significant decrease from 2020 (10%; p=0.015), whilst almost one-tenth 
(9%) reported non-prescribed use, stable from 2020 (9%; p=0.991) (Figure 28). There were no 
jurisdictional changes in the per cent reporting recent non-prescribed use (Table 11). 
Frequency of Use: Frequency of non-prescribed use remained relatively stable in 2021 at a median 
of 6 days (IQR=2-49; 10 days in 2020; IQR=2-25; p=0.571) (Figure 28).   
Recent Injection: Of those who had recently used buprenorphine-naloxone (n=135), over two-fifths 
(41%) of participants reported injecting it, stable from 35% in 2020 (p=0.377). Participants reported 
injecting buprenorphine-naloxone on a median of 6 days (IQR=2-90) in the past six months (24 days 
in 2020; IQR=2-90; p=0.384).   






Figure 28: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed buprenorphine-naloxone, nationally, 2006-2021 
 
Note. From 2006-2011 participants were asked about the use of buprenorphine-naloxone tablet; / Not asked; from 2012-2016 participants were asked about the use of buprenorphine-naloxone tablet 
and film; from 2017 onwards participants were asked about the use of buprenorphine–naloxone film only. Median days of non-prescribed use computed among those who reported recent use 
(maximum 180 days), and is only reported from 2012 onwards to capture film use. Median days rounded to the nearest whole number. Y axis reduced to 30 days to improve visibility of trends.  
*p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 8 14 17 22 23 22 26 24 25 26 19 24 20 22 18 15
% Non-Prescribed Use 3 8 9 12 13 13 14 14 15 17 11 14 10 12 9 9










































Table 11: Past six month non-prescribed use of buprenorphine-naloxone (any form), by jurisdiction, 2006-
2021 
% NSW ACT VIC TAS SA WA NT QLD 
2006 - - 5 - - 9 - 7 
2007 - 6 13 - - 15 - 24 
2008 - 10 18 - - 12 - 16 
2009 6 11 14 - 9 28 8 22 
2010 - 12 24 - 8 17 15 21 
2011 8 12 29 - - 14 14 11 
2012# 9 9 23 11 18 22 8 15 
2013 9 11 17 9 9 22 19 22 
2014 15 16 15 11 9 18 20 16 
2015 11 12 17 13 15 19 22 27 
2016 11 7 14 7 6 - 9 23 
2017^ 14 13 11 14 14 16 10 24 
2018 9 16 12 12 - 7 - 18 
2019 11 14 10 7 8 16 10 22 
2020 - - 4 23 11 12 - 15 
2021 - 9 5 21 10 13 - 11 
Note. Data collected from 2006 onwards. # Includes ‘tablet’ and ‘film’ forms from 2012-2016. ^ Includes only ‘film’ form from 2017 onwards. 
- Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 







Any Recent Use (past 6 months): After remaining relatively stable from 2001-2007, the per cent 
reporting recent morphine use has been declining from 2008 onwards (Figure 29). In 2021, 19% of 
the national sample had recently used any morphine (19% in 2020), the lowest percentage reporting 
recent use since the commencement of monitoring. Nationally, this per cent mostly comprised non-
prescribed use (16% in 2021; 15% in 2020; p=0.600), with non-prescribed use lowest in the VIC 
sample (6%) and highest in the TAS sample (40%) (Table 12). Four per cent of the national sample 
in 2021 reported recent prescribed use (4% in 2020; p=0.612). 
Frequency of Use: Frequency of non-prescribed morphine use has fluctuated over time, though 
remained stable in 2021 at a median of 10 days (IQR=3-54; 12 days in 2020; IQR=3-90; p=0.676) 
(Figure 29).  
Recent Injection: Of those who had recently used morphine (n=167), the majority (84%) reported 
injecting it, stable relative to 2020 (85%; p=0.915). Those who reported injecting morphine did so on 
a median of 11 days (IQR=3-90) in the six months preceding interview, stable from 2020 (12 days; 
IQR=3-90; p=0.926).   
Oxycodone 
Any Recent Use (past 6 months): After a gradual increase from 2005 to 2012, the per cent reporting 
recent oxycodone use has been declining (Figure 30). In 2021, 14% of the national sample had 
recently used any oxycodone, stable relative to 2020 (14%; p=0.972). Five per cent of the sample 
reported prescribed use (4% in 2020; p=0.074), and nearly one-tenth (9%) reported non-prescribed 
use (11% in 2020; p=0.420). The per cent reporting non-prescribed oxycodone use has declined 
across all jurisdictions from 2012 onwards (Table 13). 
Frequency of Use: In 2021, participants reported using non-prescribed oxycodone on a median of 
four days (IQR=2-12; 4 days in 2020; IQR=2-12, p=0.878).  
Recent Injection: Of those who had recently used oxycodone (n=120), over two-fifths (43%) of 
participants reported injecting it, a significant reduction relative to 2020 (63%; p=0.002). The median 
days injected in the past six months remained stable (5 days; IQR=2-14; 5 days in 2020; IQR=2-24; 
p=0.537). 
 






Figure 29: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed morphine, nationally, 2001-2021 
 
Note. Non-prescribed use not distinguished in 2001-2005 (/ Not asked). Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest 






2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 43 50 47 49 44 52 53 50 44 46 43 43 38 37 31 29 29 26 22 19 19
% Non-Prescribed Use 47 49 47 40 42 39 38 35 35 28 26 24 22 18 15 16



































Table 12: Past six month non-prescribed use of morphine, by jurisdiction, 2006-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2006 31 52 31 58 48 52 70 51 
2007 34 53 37 67 41 45 73 57 
2008 31 35 40 81 30 31 85 51 
2009 28 38 31 81 22 33 61 38 
2010 31 36 30 73 24 28 89 38 
2011 21 30 33 73 20 33 72 39 
2012 21 30 27 64 23 43 69 34 
2013 19 23 20 65 22 37 74 38 
2014 25 12 24 71 20 27 80 32 
2015 19 20 13 47 20 19 69 29 
2016 16 12 10 51 18 16 71 33 
2017 16 21 7 42 12 18 60 26 
2018 17 10 10 47 7 14 54 29 
2019 13 11 9 26 10 15 40 28 
2020 7 8 8 38 11 18 32 21 
2021 9 9 6 40 8 16 36 18 
Note. From 2001-2005, the IDRS did not distinguish between prescribed and non-prescribed morphine. *p<0.050; **p<0.010; ***p<0.001 














Figure 30: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed oxycodone, nationally, 2005-2021 
 
Note. From 2005-2015, participants were asked about recent use and frequency of use for any oxycodone; from 2016-2018, recent use and frequency of use for oxycodone was broken down into 
three types: tamper resistant (‘OP’), non-tamper proof (generic) and ‘other oxycodone’ (/ median days non-prescribed use missing from 2016-2018). From 2019, recent use for oxycodone was broken 
down into four types: tamper resistant (‘OP’), non-tamper proof (generic), ‘other oxycodone’ and oxycodone-naloxone, while frequency of use was asked for any oxycodone. Median days of non-
prescribed use computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 14 days to improve visibility of trends. 
*p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 21 26 30 30 32 32 36 39 36 33 25 21 20 17 18 14 14
% Non-Prescribed Use 18 23 28 28 30 28 32 35 32 29 21 18 17 14 15 11 9











































Table 13: Past six month non-prescribed use of oxycodone, by jurisdiction, 2005-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2005 14 14 16 30 11 39 11 16 
2006 18 22 24 29 20 42 7 21 
2007 26 23 28 36 20 44 11 39 
2008 27 27 25 53 15 23 28 26 
2009 27 27 25 56 9 29 35 34 
2010 33 13 28 60 17 20 22 26 
2011 34 23 37 45 23 30 26 34 
2012 46 34 26 56 26 48 19 29 
2013 40 17 23 61 18 33 23 37 
2014 40 16 22 47 21 27 22 38 
2015 21 15 19 27 25 18 23 24 
2016 23 12 10 28 16 17 18 22 
2017 27 9 8 29 13 14 14 18 
2018 16 10 10 28 - 15 11 18 
2019 21 14 5 22 13 11 12 20 
2020 9 8 7 24 11 8 9 15 
2021 9 - 7 17 9 15 - 10 
Note. Data on oxycodone use not collected from 2000-2005. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; 
***p<0.001 for 2020 versus 2021. 
 
  







Any Recent Use (past 6 months): The per cent reporting recent use of fentanyl has remained low 
since monitoring began (Figure 31), with 8% reporting recent use in 2021 (7% in 2020; p=0.698) 
(Figure 31). Six per cent reported non-prescribed use (6% in 2020; p=0.724) and 2% reported 
prescribed use (1% in 2020; p=0.127). Non-prescribed use was highest in the TAS and the ACT 
samples (12% and 10%, respectively) (Table 14). 
Frequency of Use: In 2021, participants reported non-prescribed use on a median of four days 
(IQR=2-11) in the past six months, a significant increase relative to 2020 (2 median days; IQR=1-7; 
p=0.046).   
Recent Injection: Of those who had recently used fentanyl (n=69), the majority (83%) reported 
injecting it (91% in 2020; p=0.273) and had done so on a median of three days (IQR=1-7) in the past 
six months (2 days in 2020; IQR=1-6; p=0.461).   
 






Figure 31: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed fentanyl, nationally, 2013-2021 
Note. Data on fentanyl use not collected from 2000-2012; from 2013-2017, the IDRS did not distinguish between prescribed and non-prescribed use (/ Not asked). Median days computed among 
those who reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. *p<0.050; **p<0.010; ***p<0.001 for 





2013 2014 2015 2016 2017 2018 2019 2020 2021
% Any Use 8 9 10 10 9 8 11 7 8
% Non-Prescribed Use 7 9 6 6















































Table 14: Past six month non-prescribed use of fentanyl, by jurisdiction, 2018-2021 
 
% NSW ACT VIC TAS SA WA NT QLD 
2018 6 6 8 0 - 8 - 16 
2019 11 10 7 - - 9 13 13 
2020 8 9 - - 10 11 - - 
2021 7 10 - 12 6 6 - - 
Note. Data on fentanyl use not collected from 2000-2012; from 2013-2017, the IDRS did not distinguish between prescribed and non-
prescribed use. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
 
Other Opioids  
Participants were asked about prescribed and non-prescribed use of other opioids (Table 15). In 2021, 
one-tenth (10%) of participants reported any recent use of codeine, with 6% reporting prescribed use 
(7% in 2020; p=0.357), and 5% reporting non-prescribed use (4% in 2020; p=0.438). Of those who 
reported recent use and commented (n=89), 2% reported recent injection, stable from 7% in 2020 
(p=0.300).  
In 2021, 8% reported any recent use of tramadol (7% in 2020; p=0.305), with 4% reporting prescribed 
use (4% in 2020; p=0.829) and 5% reporting non-prescribed use (4% in 2020; p=0.357). Of those 
reporting recent use (n=74), over one-tenth (11%) reported recent injection (8% in 2020; p=0.826). 
Two per cent of the sample reported recent use of tapentadol in 2021 (1% in 2020; p=0.567), with 1% 
reporting prescribed use (1% in 2020; p=0.461). Small numbers (n≤5) reported recent non-prescribed 
use in 2021 (n≤5 in 2020) and no one reported recent injection (n≤5 in 2020; p=0.126) 
Very few participants (n≤5) reported any recent use of other opioids (Table 15). 
Table 15: Past six month use of other opioids, nationally, 2019-2021 





Codeine^    
Prescribed use 14 7 6 
Non-prescribed use 9 4 5 
Any injection# 5 7 2 
Tramadol    
Prescribed use 10 4 4 
Non-prescribed use 7 4 5 
Any injection# 9 8 11 
Tapentadol    
Prescribed use - 1 1 
Non-prescribed use 1 - - 
Any injection# - - 0 
Note. - Values suppressed due to small cell size (n≤5 but not 0). ^Includes high and low dose. #Of those who reported past six month use. 

















Participants were asked about their recent (past six month) use of 
various other drugs, including use of new psychoactive substances, 
non-prescribed use (i.e., use of a medicine obtained from a 
prescription in someone else’s name) of other pharmaceutical drugs, 
and use of licit substances (e.g., alcohol, tobacco). 






New Psychoactive Substances (NPS) 
NPS are often defined as substances which do not fall under international drug control, but which may 
pose a public health threat. However, there is no universally accepted definition, and in practicality 
the term has come to include drugs which have previously not been well-established in recreational 
drug markets.  
Recent Use (past 6 months): In 2021, 7% reported any recent NPS use, the lowest per cent 
observed since monitoring began (8% in 2020; p=0.379) (Table 16). ‘New’ drugs that mimic the effects 
of cannabis were the most commonly used NPS (4%), although use was infrequent (median 2 days; 
IQR=1-120). A small per cent (1%) reported use of new drugs that mimic the effects of opioids.  
Table 16: Past six month use of new psychoactive substances, nationally, 2013-2021 
% 2013 2014 2015 2016 2017 2018 2019 2020 2021 
 N=887 N=898 N=888 N=877 N=888 N=905 N=902 N=884 N=887 
‘New’ drugs that mimic the effects of opioids / / / / - - 2 1 1 
‘New’ drugs that mimic the effects of ecstasy / / / / 1# 1 2 - 1 
‘New’ drugs that mimic the effects of 
amphetamine or cocaine 4 4 3 4 / 2 1 2 1 
‘New’ drugs that mimic the effects of cannabis 9 8 8 8 5 5 6 5 4 
‘New’ drugs that mimic the effects of 
psychedelic drugs / / / / 1
# 2 1 1 - 
‘New’ drugs that mimic the effects of 
benzodiazepines / / / / / - 1 - 1 
Any of the above 12 11 10 11 8 11 11 8 7 
Note. - Values suppressed due to small cell size (n≤5 but not 0). / denotes that this item was not asked in these years. #In 2017, participants 
were asked about use of ‘new drugs that mimic the effects of ecstasy or psychedelic drugs’. *p<0.050; **p<0.010; ***p<0.001 for 2020 
versus 2021. 
 
Non-Prescribed Pharmaceutical Drugs 
Benzodiazepines 
Recent Use (past 6 months): The per cent reporting non-prescribed benzodiazepine use has been 
gradually decreasing, from 46% in 2007 when monitoring commenced to 29% in 2021, the lowest per 
cent recorded since monitoring began (31% in 2020; p=0.282) (Figure 32). Of the total sample, 16% 
reported use of non-prescribed alprazolam (15% in 2020; p=0.841) and 22% reported use of non-
prescribed other benzodiazepines (24% in 2020; p=0.520). 
Frequency of Use: In 2021, people who had used non-prescribed benzodiazepines reported a 
median of six days (IQR=2-24; 3 days in 2020; IQR=2-10; p=0.004) and 12 days (IQR=3-48; 10 days 
in 2020; IQR=3-24; p=0.520) of non-prescribed use of alprazolam and other benzodiazepines, 
respectively. 
Recent Injection: In 2021, 7% of participants who had recently used non-prescribed 
benzodiazepines reported injecting as a route of administration (6% in 2020; p=0.830).  Additionally, 
4% of participants who had recently used any benzodiazepines (including alprazolam, prescribed or 
non-prescribed) reported injecting as a route of administration (4% in 2020; p=0.987).  







Recent Use (past 6 months): Non-prescribed use of pharmaceutical stimulants (e.g., 
dexamphetamine, methylphenidate, modafinil) has decreased since monitoring began (Figure 32). 
One-fifth (18%) reported recent use in 2006, declining to 6% in 2021 (8% in 2020; p=0.191).  
Frequency of Use: Frequency of non-prescribed use remained stable at three days in 2021 (IQR=2-
8; 3 days in 2020; IQR=1-12; p=0.483).  
Recent Injection: Over one-third (35%) of those who had recently used non-prescribed 
pharmaceutical stimulants reported that they had injected it (42% in 2020; p=0.562) on a median of 
four days (IQR=3-7; 2 days in 2020; IQR=2-10; p=0.320).  
Antipsychotics 
Recent Use (past 6 months): The per cent of the sample reporting recent use of non-prescribed 
antipsychotics (asked as ‘Seroquel’ from 2011-2018) has gradually decreased over time, with 5% 
reporting use in 2021, the lowest per cent since monitoring began (6% in 2020; p=0.318) (Figure 32).  
Frequency of Use: There was an increase in frequency of use in 2021 (median 7 days; IQR=4-30) 
compared to 2020 (median 4 days; IQR=2-10; p=0.039). 
Recent Injection: No one reported recent injection of antipsychotics in 2021 (not asked in 2020). 
Pregabalin 
Recent Use (past 6 months): In 2021, 16% of the national sample reported non-prescribed 
pregabalin use in the six months preceding interview (14% in 2020; p=0.245) (Figure 32), with the 
highest per cent of use observed in the TAS and QLD samples (23% and 22%, respectively).  
Frequency of Use: Non-prescribed use was infrequent, with a reported median of six days of use in 
2021 (IQR=2-24), consistent with 2020 reports (median 6 days; IQR=2-24; p=0.859).  
Recent Injection: Of those who had recently used non-prescribed pregabalin, 6% reported recent 
injection (11% in 2020; p=0.208) on a median of 5 days (IQR=2-11; not asked in 2020).  
  






Figure 32: Past six month use of non-prescribed pharmaceutical drugs, nationally, 2006-2021 
 
Note. Non-prescribed use is reported. Participants were first asked about antipsychotics in 2011 (asked as ‘Seroquel’ 2011-2018) and pregabalin in 2018. Pharmaceutical stimulants were separated 
into prescribed and non-prescribed from 2006 onwards, and benzodiazepines were separated into prescribed and non-prescribed in 2007. / Not asked. *p<0.050; **p<0.010; ***p<0.001 for 2020 
versus 2021. 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Benzodiazepines 46 45 44 40 53 50 47 44 43 38 32 30 32 31 29
Pharmaceutical stimulants 18 14 14 12 13 14 13 11 13 10 9 7 9 7 8 6
Antipsychotics 15 16 10 12 12 10 12 11 9 6 5




























Licit and Other Drugs 
Steroids 
Recent Use (past 6 months): Reports of recent use of non-prescribed steroids have remained 
consistently low (between <1% and 3%) since monitoring began in 2010. Few participants (n≤5) 
reported recent use in 2021.  
Alcohol 
Recent Use (past 6 months): Fifty-two per cent of the sample reported recent use of alcohol in 2021 
(54% in 2020; p=0.338) (Figure 33).  
Frequency of Use: Median frequency of use amongst those who reported alcohol use in 2021 was 
36 days (IQR=6-150; 24 days in 2020; IQR=6-96; p=0.153), with 22% reporting daily use (19% in 
2020; p=0.272). 
Tobacco 
Recent Use (past 6 months): Tobacco use has remained relatively high since the IDRS began. In 
2021, the majority of the national sample reported recent use (90%; 89% in 2020; p=0.374) (Figure 
33).  
Frequency of Use: Frequency of use remained high among those reporting recent use at a median 
of 180 days (IQR=180-180 days; 180 days in 2020; IQR=180-180; p=0.836), with 91% reporting daily 
use in 2021 (91% in 2020). 
E-cigarettes 
Recent Use (past 6 months): There was a significant increase in recent e-cigarette use in 2021 
(18%; 13% in 2020; p=0.002), returning to the percentages observed in 2018 and 2019 (Figure 33). 
Frequency of Use: Frequency of use remained stable in 2021 at a median of 19 days (IQR=5-120; 
20 days in 2020; IQR=3-160; p=0.624), with 23% of recent consumers reporting daily use (24% in 
2020; p=0.985). 
Forms Used: Among those who reported recent use and commented (n=150), the majority (88%) 
reported using e-cigarettes containing nicotine (74% in 2020; p=0.003), followed by 9% who reported 
using e-cigarettes containing cannabis (n≤5 in 2020; p=0.097) and 9% who reported using e-
cigarettes containing both nicotine and cannabis (5% in 2020; p=0.042). Twelve per cent reported 
using e-cigarettes that contained neither cannabis nor nicotine (17% in 2020; p=0.065).  
Reason for Use: Nearly two-fifths (38%) of those who had recently used e-cigarettes in 2021 reported 
that they did not use e-cigarettes as a smoking cessation tool, a significant decrease from 2020 (57%; 
p=0.002). 
GHB/GBL/1, 4-BD 
Recent Use (past 6 months): In 2021, 10% of the sample reported recent use of GHB/GBL/1,4-BD 
(10% in 2020; p=0.964) (Figure 33). 
 






Recent Injection: Of those that reported recent use, 6% reported injection as a route of administration 
(n≤5 in 2020).  






Figure 33: Past six month use of licit and other drugs, nationally, 2000-2021 
Note. Participants were first asked about e-cigarettes in 2014. Participants were first asked about GHB/GBL/1,4-BD in 2020. / Not asked. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Alcohol 68 71 68 71 68 67 68 64 60 64 64 65 64 59 58 61 58 56 62 59 54 52
Tobacco 92 93 94 94 94 94 95 95 94 93 93 94 94 91 92 92 93 88 93 94 89 90









































Participants were asked about various drug-related harms and 
associated behaviours, including non-fatal overdose, injecting risk, 
drug treatment, mental health and crime. It should be noted that the 
following data refer to participants’ understandings of these 
behaviours (e.g., may not represent medical diagnoses in the case of 
reporting on health conditions).  








In 2021, the majority (98%) of the sample reported using one or more drugs (including alcohol, 
tobacco and prescription medications) on the day preceding interview. Of those who reported using 
one or more drugs (n=865), the most commonly used substances were tobacco (73%), opioids (51%), 
cannabis (45%), stimulants (38%), and benzodiazepines (17%).  
Approximately one-in-ten participants reported concurrent use of cannabis and stimulants (11%) and 
cannabis and opioids (11%) on the day preceding interview (Figure 34). Twenty per cent of 
respondents reported using opioids alone, whilst 14% reported using stimulants alone.  
Figure 34: Use of opioids, stimulants, benzodiazepines and cannabis on the day preceding interview and 
most common drug pattern profiles, nationally, 2021 
 
Note. % calculated out of total IDRS 2021 sample. The horizontal bars represent the per cent of participants who reported use of each drug 
class on the day preceding interview; the vertical columns represent the per cent of participants who used the combination of drug classes 
represented by the blue circles. Participants who did not report use of any of the four drug classes depicted are not shown in the figure but 
are counted in the denominator. ‘Stimulants’ includes methamphetamine, cocaine, MDA, MDMA, OTC stimulants and/or pharmaceutical 
stimulants. ‘Opioids’ includes heroin, methadone, morphine, oxycodone, buprenorphine, buprenorphine-suboxone, fentanyl, other 
pharmaceutical opioids (codeine, tapentadol, tramadol, etc). Use of benzodiazepines, opioids and stimulants could be prescribed or non-





There has been some variation in the way questions about overdose have been asked over the years.  
In 2021, participants were asked about their past 12-month experience of overdose where symptoms 
aligned with the examples provided and effects were outside their normal experience, or they felt 
professional assistance may have been helpful. We specifically asked about: 






• Opioid overdose (e.g., reduced level of consciousness, respiratory depression, turning 
blue, collapsing and being unable to be roused). Participants who reported this experience 
were asked to identify all opioids involved in such events in the past 12 months; 
• Non-opioid overdose (e.g., nausea, vomiting, chest pain, tremors, increased body 
temperature, increased heart rate, seizure, extreme paranoia, extreme anxiety, panic, extreme 
agitation, hallucinations). Drugs other than opioids were split into the following: 
- Stimulant overdose: Stimulant drugs include ecstasy, methamphetamine, cocaine, MDA, 
methylone, mephedrone, pharmaceutical stimulants and stimulant NPS (e.g., MDPV, 
Alpha PVP); and 
- Other drug overdose: ‘Other drugs’ include (but are not limited to) alcohol, cannabis, 
GHB/GBL/1,4-BD, amyl nitrite/alkyl nitrite, benzodiazepines and LSD.  
 
It is important to note that overdose episodes reported across the drug types may not be unique given 
high rates of polysubstance use amongst the sample. Each year we compute the total per cent of 
participants who have experienced any past 12-month overdose event by looking for any 
endorsement across the drug types queried (see below); however, please note that estimates may 
vary over time because of changes in how questions have been asked.  
After some fluctuations from 2000-2006 (likely due to differences in the way questions regarding 
overdose were asked), the per cent reporting any past 12-month non-fatal overdose remained 
relatively stable from 2007-2017. After a slight increase in 2018 and 2019 (20% and 21%, 
respectively; p=0.691), the per cent reporting any past 12-month non-fatal overdose in 2021 remained 
relatively stable (17%; 18% in 2020) (Figure 35). In 2021, the per cent reporting any past 12-month 
non-fatal overdose was highest in the NSW and VIC samples (24%, respectively) and lowest in the 
NT sample (n≤5) (Table 17).  
Eleven per cent reported a non-fatal overdose following opioid use in the past 12 months (13% in 
2020; p=0.300), whilst 7% reported a non-fatal overdose following stimulant use in the past 12 
months (6% in 2020; p=0.351) (Table 17).  
The most commonly cited substance involved in past year non-fatal overdoses was heroin (9% of the 
total sample in 2021). Participants who had overdosed on an opioid had done so on a median of one 
occasion (IQR=1-2) in the last 12 months. Among those that had overdosed on an opioid in the past 
year and commented (n=98), 34% reported that an ambulance had attended their most recent 
overdose, 43% reported receiving Narcan®, 19% were admitted to an emergency department and 
14% reported receiving oxygen. Twenty-four per cent reported not receiving any treatment. The most 
commonly cited drugs involved in participants’ most recent opioid overdose were benzodiazepines 
(including alprazolam, 31%), alcohol (20%), cannabis (20%) and crystal methamphetamine (16%). 
Please contact the Drug Trends team (drugtrends@unsw.edu.au) to request further findings 











Figure 35: Past 12-month any non-fatal overdose, nationally, 2000-2021 
 
 
Note. Estimates from 2000-2005 refer to heroin and morphine non-fatal overdose only. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
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Table 17: Past 12-month non-fatal overdose by drug type, nationally and by jurisdiction, 2020-2021 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=884 N=888 N=150 N=100 N=148 N=95 N=101 N=99 N=94 N=101 
 2020 2021         




































































































% Other drug overdose            




8 6 6 9 9 10 - 6 








































Note. Participants reported on whether they had overdosed following use of the specific substances; other substances may have been 
involved on the occasion(s) that participants refer to.  – Values suppressed due to small numbers (n≤5 but not 0). N is the number who 
responded (denominator). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021 for national estimates. 
 
Naloxone Program and Distribution 
Naloxone is a short-acting opioid antagonist that has been used for over 40 years to reverse the 
effects of opioids. In 2012, a take-home naloxone program commenced in the ACT (followed by NSW, 
VIC, and WA) through which naloxone was made available to peers and family members of people 
who inject drugs for the reversal of opioid overdose. In early 2016, the Australian Therapeutic Goods 
Administration (TGA) placed ‘naloxone when used for the treatment of opioid overdose’ on a dual 
listing of Schedule 3 and Schedule 4, meaning naloxone can be purchased OTC at pharmacies 
without a prescription, and at a reduced cost via prescription. In 2020 and 2021, under the take home 
naloxone pilot program, naloxone was made available free of charge and without a prescription in 
NSW, SA and WA. Furthermore, naloxone nasal spray (Nyxoid) is now available in Australia as a 
PBS-listing, which is expected to increase use of naloxone in the community.  
Awareness of Naloxone: From 2013-2021, there has been no significant change in the per cent of 
the national sample who have heard of naloxone, with over four in five participants reporting 
awareness of naloxone in each year (81% in 2021) (Figure 36). There was large variation across the 
jurisdictions in the per cent of participants who had heard of naloxone. The ACT sample (96%) had 
the highest per cent of participants who reported having ever heard of naloxone, whilst the NT sample 
(45%) had the lowest per cent (Table 18).  
Awareness of Take-Home Programs (training program): In 2021, over three-fifths of participants 
(64%) had heard about the take-home naloxone programs (65% in 2020; p=0.547) (Figure 36). In 
2021, knowledge regarding the take-home naloxone program (and participation in this program) was 






highest among the ACT sample (88% and 58%, respectively), followed by the WA sample (80% and 
56%, respectively) (Table 18). 
Participation in Training Programs: In 2021, nearly two-fifths (37%) had been trained in how to 
administer naloxone in their lifetime (34% in 2020; p=0.320) (Figure 36). Participation in the naloxone 
training programs ranged from 9% in the TAS sample to 58% in the ACT sample (Table 18). Over 
half of those participating in the naloxone training program had completed their last naloxone training 
via a needle and syringe program (NSP; 52%), followed by 15% via a health service and 12% via a 
drug treatment service. 
Accessed Naloxone: In 2021, 51% of the total sample reported having ever accessed naloxone, 
with 4% reporting that they had tried to access naloxone but been unsuccessful. Out of those that had 
never accessed naloxone (n=552), the reasons why they had not accessed it were ‘didn’t consider 
myself/my peers at risk of overdose’ (22%), ‘don’t use opioids’ (20%) and ‘didn’t know you could 
access naloxone’ (13%).  
Of those who reported to have accessed naloxone and could respond (n=361), on the last occasion 
nearly two-fifths (39%) received the intramuscular naloxone and nearly half (47%) received intranasal 
naloxone. On the last occasion over half (52%) accessed naloxone via a needle and syringe program 
(NSP), followed by a health service (15%) and a drug treatment service (12%). The majority (96%) 
did not have to pay the last time they accessed naloxone. Of those that had accessed naloxone and 
could respond (n=364), over half (51%) reported that they ‘always’ had naloxone on hand when using 
opioids in the past month, followed by 18% reporting ‘never’, 10% ‘often’, 8% ‘sometimes’ and 7% 
‘rarely’. 
Use of Naloxone to Reverse Overdose: In 2021, of those that reported to have heard about 
naloxone and could respond (n=716), over one-quarter (29%) reported that they had resuscitated 
someone using narcan/naloxone at least once in their lifetime (23% in 2020; p=0.089). Of those who 
reported past year opioid overdose and could respond (n=96), over-one third (36%) reported that they 
had been resuscitated by a peer using narcan/naloxone. 
In 2021, of those that responded (n=886), 4% reported that they had ever been resuscitated by a peer 
















Figure 36: Take-home naloxone program and distribution, nationally, 2013-2021 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021. 
 
Table 18: Awareness of take-home naloxone program and distribution, by jurisdiction, 2021 
 
 NSW ACT VIC TAS SA WA NT QLD 
 N=150 N=100 N=148 N=95 N=101 N=99 N=94 N=101 
% Heard of naloxone 93 96 90 84 58 90 45 81 
% Heard of the take-
home naloxone program 
74 88 77 53 32 80 34 60 
% Trained in naloxone 
administration 
44 58 53 9 17 56 13 30 
Note. N is the number who responded (denominator).  
 
 
Injecting Risk Behaviours and Harms 
Injecting Risk Behaviours 
In 2021, 6% nationally reported receptive sharing (5% in 2020; p=0.753) and 10% reporting 
distributive sharing (9% in 2020; p=0.698) in the past month. The per cent who had shared other 
injecting equipment (e.g., spoons, tourniquet, water, and filters) in the month preceding interview more 
than halved between 2000 (51%) and 2011 (25%) and remained relatively stable from 2011-2020 
(notwithstanding a sharp decline in 2019). In 2021, the per cent reporting that they had shared other 
injecting equipment in the past month (18%) declined relative to 2020 (25%; p=0.001) (Figure 37). 
The per cent of the sample who reported re-using their own needles in the past month also declined 
from 2008 to 2018, however increased and then stabilised in 2019-2020, before declining again in 
2021 (38%; 44% in 2020; p=0.006) (Figure 37). 
Over one-third (34%) of the 2021 sample reported that they had injected someone else after injecting 
themselves in the past month (32% in 2020; p=0.369) and 18% had been injected by someone else 
(17% in 2020; p=0.868).  
Consistent with previous years, most participants (83%) in the national sample reported that they had 
last injected in a private home (83% in 2020; p=0.489) (Table 19). Twelve per cent of VIC participants 
2013 2014 2015 2016 2017 2018 2019 2020 2021
Heard of naloxone 86 85 87 86 86 85 85 83 81
Heard of take-home programs 35 43 52 49 53 58 57 65 64




























reported last injecting at the Medically Supervised Injecting Room, whereas few participants (n≤5) 
reported last injecting at the Sydney Medically Supervised Injecting Centre. 






Figure 37: Borrowing and lending of needles and sharing of injecting equipment in the past month, nationally, 2000-2021 
 
Note. Data collection for ‘reused own needle’ started in 2008 (/ Not asked). Borrowed (receptive): used a needle after someone else. Lent (distributive): somebody else used a needle after them. 




2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Borrowed needles 16 13 12 9 11 11 9 10 7 9 10 11 7 7 6 7 7 7 9 8 5 6
Lent needles 11 17 16 16 17 17 15 17 11 18 16 16 14 11 13 11 11 12 11 11 9 10
Shared other equipment 51 45 37 34 45 37 33 37 38 37 39 25 25 24 26 25 26 20 19 5 25 18






























Table 19: Sharing needles and injecting equipment in the past month, nationally and by jurisdiction, 2020-
2021 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=884 N=888 N=150 N=100 N=148 N=95 N=101 N=99 N=94 N=101 










































































































































% Location of 
last injection N=878 N=884 N=149 N=100 N=148 N=94 N=101 N=99 N=94 N=99 
Private home 83 83 87 89 66 93 91 70 91 87 
Car 5 4 5 - - - 0 10 - - 
Street/car 
park/beach 5 4 5 - 11 - - - - - 





3 3 - / 12 / / / / / 
Other 1 2 - - - 0 0 - - - 
Note. ^ Includes spoons, water, tourniquets and filters; excludes needles/syringes. ~ With a new or used needle. Borrowed (receptive): used 
a needle after someone else. Lent (distributive): somebody else used a needle after them. - Values suppressed due to small cell size (n≤5 




Self-Reported Injection-Related Health Problems 
In 2021, over one-quarter (26%) of the national sample reported having an injection-related health 
issue in the month preceding interview, stable from 2020 (29%; p=0.155) (Table 20). The most 
common injection-related health issue reported by participants was nerve damage (11%; 12% in 













Table 20: Injection-related issues in the past month, nationally and by jurisdiction, 2020-2021 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=879 N=885 N=149 N=99 N=148 N=95 N=101 N=98 N=94 N=101 
 2020 2021         
   % Artery Injection 7 6 9 8 - 8 6 - - 10 
% Nerve damage 12 11 13 - 7 7 13 13 0 27 
% Any thrombosis 7 6 7 - 9 6 6 - 0 8 
Blood clot 6 5 7 - 7 - 6 - 0 7 
Deep vein 
thrombosis 2 1 - - - - 0 0 0 - 
% Any infection/ 
abscess 8 8 9 - 7 8 12 14 - 9 
Skin abscess 7 7 8 - 7 7 10 10 - - 
Other serious 
infection (e.g. sepsis, 
osteomyelitis) 
2 1 0 0 - - - - 0 - 
Endocarditis - 1 - 0 - - - 0 0 - 
% Dirty hit 8 7 11 - 5 - 11 10 - 13 
% Any injection 
related problem 29 26 32 18 24 23 29 33 - 42 
Note. In 2020, ‘sepsis’ and osteomyelitis were combined. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; 




In 2021, nearly two-fifths (37%) reported that they were currently in any drug treatment for their 
substance use (most commonly methadone), which was a significant decrease relative to 2020 (48%; 
p<0.001) (Table 21).  
In 2021, of those not currently in treatment (n=557), 13% reported having difficulties accessing 
treatment in the past six months. Among the participants that experienced difficulties accessing 
treatment (n=66), methamphetamine (60%) and heroin (27%) were the main substances for which 
participants intended to seek treatment. Residential rehabilitation/therapeutic community (41%), 
counsellor (25%), detoxification (19%), GP (14%) and opioid substitution program (10%) were the 






















Table 21: Current drug treatment, nationally and by jurisdiction, 2020-2021 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=884 N=886 N=149 N=100 N=148 N=95 N=101 N=99 N=94 N=101 
 2020 2021         
% Current drug treatment 48 37*** 50 52 34 29 24 46 11 45 
Methadone 31 24** 40 41 29 12 15 28 6 22 
Buprenorphine 2 2 - - 0 - - - - 8 
Buprenorphine-naloxone 8 5* 7 12 - 6 - 9 - 12 
Buprenorphine depot injection  2 2 - - 5 - - - - - 
Drug counselling 11 8* 13 9 5 14 11 15 - 22 
Other 4 4 4 8 4 9 9 10 - - 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2020 versus 2021 for national 
estimates. 
 
Bloodborne Virus Testing and Treatment 
In 2021, over two-fifths (44%) of participants reported that they had received a hepatitis C virus (HCV) 
antibody test in the past year (a decrease relative to 2020; 31%; p<0.001), 40% had received an RNA 
test (36% in 2020; p=0.108) and 9% reported having a current HCV infection (11% in 2020; p=0.363) 
(Table 22). Twelve per cent of the total sample reported that they had received HCV treatment in the 
past year, of which the majority (69%; n=72) reported that their treatment had been successful. 
 
Over four-fifths of the sample (84%) reported having ever had a test for human immunodeficiency 
virus (HIV) (31% within the past six months), with the vast majority reporting that they had never 
































Table 22: HCV and HIV testing and treatment, nationally and by jurisdiction,2020-2021 
% National NSW ACT VIC TAS SA WA NT QLD 
 N=884 N=888 N=150 N=100 N=148 N=95 N=101 N=99 N=94 N=101 
 2020 2021         
Past year Hepatitis C 
test (n) 
          






















Past year hepatitis C 





















Current hepatitis C 
status (n) 























Past year treatment 
for hepatitis C (n) 
          






















Most recent treatment 
was successful 
(among those who had 






















HIV test (n)  N=727 N=147 N=97 N=143 N=87 N=99 N=98 N=94 N=99 
HIV test in past 6 
months 
















HIV test more than 6 
months ago 
















HIV status (n)  N=727 N=147 N=96 N=143 N=84 N=98 N=98 N=94 N=99 
Lifetime HIV positive 
diagnosis  
/ 3 7 - 5 0 - - - - 
Note. - Values suppressed due to small numbers (n≤5 but not 0). N is the number who responded (denominator). Timeframes for HCV and 
HIV differ; i.e., HCV questions focus on lifetime and past year; HIV questions focus on lifetime and past six months. / Not asked. *p<0.050; 
**p<0.010; ***p<0.001 for 2020 versus 2021 for national estimates. 
 
Mental Health  
In 2021, 47% of the sample self-reported that they had experienced a mental health problem in the 
preceding six months, stable from 2020 (47%; p=0.747) (Figure 38). Amongst those who had 
experienced a mental health problem, the most commonly reported problems were depression (64%; 
70% in 2020; p=0.486) and anxiety (49%; 55% in 2020; p=0.288). Smaller proportions reported post-
traumatic stress disorder (25%), schizophrenia (15%) and bipolar disorder (12%).  
One-quarter of the total sample (28%; 58% of those who reported a mental health problem) had seen 
a mental health professional during the past six months, stable from 2020 (53%; p=0.131). Three-
quarters (75%) of those who reported having seen a health professional about a mental health 
problem had been prescribed medication for their mental health problem in the preceding six months 










Figure 38: Self-reported mental health problems and treatment seeking in the past six months, nationally, 
2004-2021 
 
Note. The combination of the per cent who report treatment seeking and no treatment is the per cent who reported experiencing a mental 




Of the national sample, over one-third (36%) had driven a car, motorcycle or other vehicle in the last 
six months. Four per cent of the sample reported driving while over the perceived legal limit of alcohol 
(12% of those who had driven recently) and 25% reported driving within three hours of consuming an 
illicit or non-prescribed drug in the last six months (70% of those who had driven recently) (Table 23). 
Among those who reported driving within three hours of consuming an illicit or non-prescribed drug in 
the last six months, the majority reported using crystal methamphetamine prior to driving (59%), 










2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
No treatment seeking 13 11 11 7 14 13 11 14 18 12 11 12 14 14 15 16 22 19





























Table 23: Driving behaviour in the last six months, nationally and by jurisdiction, 2021 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=875 N=148 N=96 N=147 N=91 N=101 N=99 N=94 N=99 
% Driven in last six months 36 32 22 29 43 38 41 43 47 
% Driven over the legal 




















% Driven within three hours of 




















% Tested for drug driving by 
police roadside drug testing 



















% Breath tested for alcohol 




















Note: Questions about driving behaviour were not asked in 2020. 
 
Figure 39: Self-reported driving in the past six months, over the (perceived) legal limit for alcohol and three 
hours following illicit drug use, nationally, 2007-2021 
Note. Computed of the entire sample. Questions about driving behaviour were first asked about in 2007. Questions about driving behaviour 







2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Driven in past 6 months 51 53 53 47 46 45 49 51 49 47 39 45 36
Drink driving 7 7 7 5 4 4 4 5 4 6 2 6 4
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Drug checking is a common strategy used to test the purity and contents of illicit drugs. 
In 2021, 14% of participants reported that they or someone else had ever tested the content and/or 
purity of their illicit drugs in Australia (8% in the past year). Of those who reported that they or someone 
else had tested their illicit drugs in the past year (n=69), nearly half (48%) reported using colorimetric 
or reagent test kits, followed by 47% using testing strips (e.g., BTNX fentanyl strips or other 
immunoassay testing strips). Of those who had used testing strips (n=27), 59% reported getting a 
positive detection for fentanyl.  
Crime  
The per cent of participants reporting past month criminal activity declined from 2000 to 2010, 
stabilising from 2010 onwards. Property crime and selling drugs for cash profit remained the most 
common self-reported crimes in 2021 (25% and 24%, respectively), with few participants reporting 
past month violent crime (4%; 4% in 2020; p=0.696) or fraud (3%; 4% in 2020; p=0.365) (Figure 40). 
In 2021, there was a significant increase in those who reported being a victim of a crime involving 
violence (e.g., assault) in the month preceding interview (16%; 12% in 2020; p=0.016). 
In 2021, 31% of the sample had been arrested in the past year (26% in 2020; p=0.050). This ranged 
from 15% in the NT sample to 39% in both the VIC and QLD samples. Three-fifths of the national 
sample (60%) reported a lifetime prison history in 2021, stable compared to 2020 (56%; p=0.080). 











Figure 40: Self-reported criminal activity in the past month, nationally, 2000-2021 
 





2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Property crime 19 20 26 22 24 21 20 22 18 24 21 22 18 18 18 17 19 21 24 24 23 25
Drug dealing 41 39 38 34 31 30 32 29 30 29 25 25 24 23 25 27 26 25 26 28 25 24
Fraud 12 9 10 6 7 7 7 4 4 4 4 3 5 2 4 4 4 4 4 5 4 3
Violent crime 7 9 8 7 6 9 6 7 4 6 6 6 3 3 5 4 4 5 3 7 4 4
Any crime 54 52 55 49 48 46 45 42 41 45 39 39 37 36 38 39 39 40 42 45 40 39
0
10
20
30
40
50
60
70
80
90
100
%
 ID
R
S 
Pa
rt
ic
ip
an
ts
